EP2043666A2 - Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé - Google Patents

Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé

Info

Publication number
EP2043666A2
EP2043666A2 EP07766828A EP07766828A EP2043666A2 EP 2043666 A2 EP2043666 A2 EP 2043666A2 EP 07766828 A EP07766828 A EP 07766828A EP 07766828 A EP07766828 A EP 07766828A EP 2043666 A2 EP2043666 A2 EP 2043666A2
Authority
EP
European Patent Office
Prior art keywords
cells
cdl
microglia
disease
myeloid cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07766828A
Other languages
German (de)
English (en)
Inventor
Michal Eisenbach-Schwartz
Oleg Butovsky
Gilad Kunis
Shay Bukshpan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP2043666A2 publication Critical patent/EP2043666A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Definitions

  • the present invention relates to methods and compositions for promoting tissue repair, for detection of damaged tissues and for delivery of drugs or detectable substances to damaged tissues and, particularly, to bone marrow-derived myeloid cells activated by some cytokines.
  • a ⁇ ⁇ -amyloid
  • AD Alzheimer's disease
  • ALS amyotrophic lateral sclerosis
  • BDNF brain-derived neurotrophic factor
  • BM bone marrow
  • BrdU 5-bromo-2'-deoxyuridine
  • CFA complete Freund's adjuvant
  • Cop 1 Copolymer 1, glatiramer acetate
  • CSF cerebrospinal fluid
  • DCs dendritic cells
  • DCX doublecortin
  • DT diphtheria toxin
  • EAE experimental autoimmune encephalomyelitis
  • EGCG (-)-epigallocatechin-3-gallate (green tea)
  • FCS fetal calf serum
  • GA glatiramer acetate, Cop 1
  • GABA ⁇ -aminobutyric acid
  • GAD-67 glutamic acid decarboxylase 67
  • GABA ⁇ -aminobutyric acid
  • GFP green fluorescent protein
  • systemic immune cells in the form of T cells directed to certain self-antigens
  • T cells can protect injured neurons from death
  • studies in rodents showing that passive transfer of T cells specific to myelin basic protein reduces the loss of RGCs after a traumatic optic nerve injury (Moalem et al., 1999).
  • T cells are also effective when directed to either cryptic or pathogenic epitopes of myelin basic protein, as well as to other myelin antigens or their epitopes (Mizrahi et al., 2002).
  • myelin antigens capable of protecting the nervous system from any type of acute or chronic insult?
  • protective T cell response is a physiologically evoked response that might not be sufficient in severe insults or might not always be properly controlled.
  • specificity of such protective T cells depends on the site of the insult.
  • the protective effect of vaccination with myelin-associated antigens is restricted to injuries of the white matter, i.e., to myelinated axons (Mizrahi et al., 2002; Avidan et al., 2004; Schori et al., 2001). If the insult is to the retina, which contains no myelin, myelin antigens have no effect.
  • the beneficial effect of the autoreactive T cells was found to be exerted via their ability to induce the CNS- resident microglia to adopt a phenotype capable of presenting antigens (Butovsky et al., 2006a, 2005, 2001 ; Schwartz et al., 2006; Shaked et al., 2004), expressing growth factors (Butovsky et al., 2006a, 2006b, 2005), and buffering glutamate (Shaked et al., 2005).
  • Cop- 1 A single injection of Cop- 1 is protective in acute models of CNS insults (Kipnis et al., 2000; Avidan et al., 2004; Kipnis. & Schwartz, 2002), while in chronic models occasional boosting is required for a long-lasting protective effect (Angelov et al., 2003).
  • vaccination with Cop-1 significantly reduces RGC loss even if the pressure remains high.
  • the vaccination does not prevent disease onset, but can slow down its progression by controlling the local extracellular environment of the nerve and retina, making it less hostile to neuronal survival and allowing the RGCs to be better able to withstand the stress (Schori et al., 2001 ; Benner et al., 2004; Kipnis & Schwartz, 2002; Kipnis et al., 2000).
  • Cop- 1 For chronic conditions occasional boosting is needed. For example, in a model of chronically elevated intraocular pressure, weekly administration of adjuvant- free Cop-1 was found to result in neuroprotection (Bakalash et al., 2005). The neuroprotective effect of Cop- 1 has been attributed in part to production of brain-derived neurotrophic factor (BDNF) (Ziemssen et al., 2002).
  • BDNF brain-derived neurotrophic factor
  • Microglia and neurodegeneration Microglia are bone marrow-derived glial cells. In addition to astrocytes and oligodendrocytes, microglia represent the third major population of glial cells within the central nervous system (CNS). Microglia are distributed ubiquitously throughout the brain and spinal cord, and one of their main functions is to monitor and sustain neuronal health; they are the immune cells of the CNS, protecting against invading microorganisms, clearing unwanted debris, producing cytokines and cross-talking with the adaptive immune system (Aloisi, 2001, Kreutzberg, 1996). Through their immunoregulatory properties the activated microglia are involved in acute CNS injury, stroke as well as inflammatory and neurodegenerative disease (Streit, 2004; 2005).
  • Microglia are mostly known for their bad reputation in neurodegenerative conditions (Kerschensteiner et al., 1999). Yet, recent studies have pointed out that microglia display a key role not only under pathological conditions and not only destructive effects; microglia are needed for supporting neuronal survival (Butovsky.et al.2006b, 2005; Shaked et al., 2005) and neural cell renewal (Butovsky et al.2006a, 2001 ; Ziv et al., 2006a), and to fighting off neurodegenerative conditions (Butovsky et al., 2006a; Simard et al., 2006).
  • microglia Several types of microglia are present which may be associated with neurons or with blood vessels, and some of these are antigen-presenting cells (APCs).
  • APCs antigen-presenting cells
  • the nature of microglial activation, either beneficial or harmful, in damaged neural tissue depends on how microglia interpret the threat (Butovsky et al., 2005).
  • the presence of microglial cells in normal undamaged neural tissue has been debated for years, it is now an accepted fact (Nimmerjahn et al., 2005), including their presence in the eye.
  • the role of microglia in inflammatory processes is controversial.
  • participation of microglia in inflammatory process of the eye can stimulate mature retinal ganglion cells (RGCs) to regenerate their axons (Yin et al., 2003).
  • microglia in neurodegenerative processes may be detrimental to the neuronal tissue.
  • Roque et al (1999) showed that microglial cells release soluble product(s) that induce degeneration of cultured photoreceptor cells. This controversy may be explained by the contradicting reports regarding the presence of APCs, which are crucial factors of an antigen-specific cell-mediated immune response.
  • Immunological responses in neural retinal microglia are related to early pathogenic changes in retinal pigment epithelium pigmentation and drusen formation.
  • Activated microglia may also be involved in rod cell death in age-related macular degeneration (AMD) and late- onset retinal degeneration.
  • a recent study has proposed that microglia, activated by primary rod cell death, migrate to the outer nuclear layer, remove rod cell debris and may kill adjacent cone photoreceptors (Gupta et al., 2003).
  • microglia Like blood-derived macrophages, microglia exhibit scavenging of extracellular deposits, and phagocytosis of abnormal amyloid deposits in Alzheimer's disease (AD). Such microglia, while efficiently acting as phagocytic cells, cause neuronal death by the secretion of mediators like tumor necrosis factor alpha (TNF- ⁇ ) (Butovsky et al., 2005), and thus, while acting as phagocytic cells (Frenkel et al., 2005). they are apparently not efficient enough to fight off the Alzheimer's disease symptoms. In contrast to these resident microglia, microglia derived from the bone marrow of matched wild-type mice can effectively remove plaques (Simard et al., 2006).
  • TNF- ⁇ tumor necrosis factor alpha
  • AMD like Alzheimer's disease, illustrates a disease in which scavenging of abnormal deposits inevitably induces self-perpetuation of disease progression mediated by the phagocytic cell themselves (Gupta et al., 2003).
  • Aggregated A ⁇ induces toxicity on resident microglia and impairs cell renewal
  • Such activities are manifested by increased production of TNF- ⁇ , down-regulation of insulin-like growth factor (IGF-I), inhibition of the ability to express class II major histocompatibility complex (MHC-II) proteins and CDl Ic (a marker of dendritic cells) and thus to act as antigen-presenting cells (APCs), and failure to support neural tissue survival and renewal ((Butovsky et al., 2006a, 2006b). Further, we found that when microglia encounter aggregated ⁇ -amyloid, their ability to remove these aggregates without exerting toxic effects on neighboring neurons or impairing neurogenesis depends upon their undergoing a phenotype switch.
  • IGF-I insulin-like growth factor
  • MHC-II major histocompatibility complex
  • CDl Ic a marker of dendritic cells
  • a switch in microglial phenotype might take place via a local dialog between microglia and T- cells, which is mediated by T cell-derived cytokines such as IL-4.
  • T cell-derived cytokines such as IL-4.
  • Addition of IL-4, a cytokine derived from T-helper (Th)-2 cells, to microglia activated by aggregated A ⁇ can reverse the down-regulation of IGF-I expression, the up-regulation of TNF- ⁇ expression, and the failure to act as APCs (Butovsky et al., 2005).
  • microglia for in-vivo neural cell renewal was demonstrated by enhanced neurogenesis in the rat dentate gyrus after injection of IL-4-activated microglia intracerebroventricularly and by the presence of IGF-I-expressing microglia in the dentate gyrus of rats kept in an enriched environment (Ziv et al., 2006a).
  • injection of IL-4-activated microglia into the cerebrospinal fluid resulted in increased oligodendrogenesis in the spinal cord and improved clinical symptoms.
  • the newly formed oligodendrocytes were spatially associated with microglia expressing MHC-II and IGF-I (Butovsky et al., 2006c).
  • the present invention relates, in one aspect, to a method for promoting tissue repair in a patient, said method comprising administering to the patient a therapeutically effective amount of CDl Ic + bone marrow-derived myeloid cells.
  • the cells express IGF-I and/or BDNF.
  • the CDl I c + bone marrow-derived myeloid cells may be obtained by activation with a cytokine selected from IL-4, 11-13 or a narrow concentration range of IFN- ⁇ of up to 20 ng/ml.
  • the present invention provides a method for detecting/localizing a damaged tissue, said method comprising administering to an individual in need bone marrow-derived myeloid cells that have been activated with IL-4, IL- 13 or up to 20 ng/ml IFN- ⁇ and labeled with an imaging agent, whereby the labeled cells traffic to the damaged tissue, and imaging the suspected area in the patient, thereby localizing the damaged tissue.
  • the invention further relates to a method for delivering a therapeutic or detectable substance to a damaged tissue or a tumor, said method comprising administering to an individual in need bone marrow-derived myeloid cells that have been activated with IL-4, IL- 13 or up to 20 ng/ml IFN- ⁇ , wherein said cells are cells that have been genetically engineered to express said therapeutic or detectable substance.
  • Figs. 1A-1F shows that in mice with chronic EAE, GA-immunization induces oligodendrogenesis.
  • Chronic EAE was induced in C57BL/6J mice. GA was administered once (s.c. in IFA) at the day of MOG-immunization (day 0; MOG in CFA).
  • IA Quantitative analysis of proliferating cells (BrdU + ) and proliferating microglia (BrdU+/ microglial marker IB4 + ) in both gray matter (GM) and white matter (WM) of the spinal cord analyzed at 300- ⁇ m intervals along longitudinal 30- ⁇ m sagittal sections (T8-T9).
  • IB NG2 + (proteoglycan oligodendrocyte marker) or RIP + (mature oligodendrocyte marker) cells co-labeled with BrdU + cells. Data are expressed as means ⁇ SEM per mm 3 .
  • IE Proliferating microglia (BrdU + /IB4 + ) co-expressing NG2 (arrows).
  • IF Appearance of newly formed oligodendrocytes (BrdU + /RIP + ) in close proximity to the central canal (CC) of MOG+GA-vaccinated mice.
  • Figs. 2A-2B show that GA- vaccination increases the number of CDl Ic + microglia in the white matter of spinal cord of chronic EAE-mice.
  • the spinal cords analyzed in Fig. 1 were also examined for microgliogenesis.
  • Asterisks above bars express the significance of differences relative to PBS-injected mice ( *** P ⁇ 0.001; two-tailed Student's Mest).
  • IB Representative confocal microscopy of longitudinal sagittal sections of spinal cords (T8-T9), stained with IB4 and co-stained with MHC-II and CDl Ic. Significantly more MHC-II + cells are seen, especially in the gray matter, in slices from myelin MOG+GA-vaccinated mice than from PBS-injected mice.
  • Fig. 3 shows that bone marrow-derived CD l Ic + cells are crucial for EAE development, but their depletion during the onset of the disease exacerbate the disease progression.
  • Lethally irradiated C57BL/J6 mice were reconstituted with syngeneic bone marrow cells of CX 3 CRlZ 017 ⁇ + ZCD] Jc DTR -transgenic mice. After 6 weeks of the transplantation, the mice were vaccinated with MOG.
  • Figs. 4A-4D show that IL-4, unlike IL-IO, induces MHC-II and CDl Ic in both microglia and bone marrow-derived myeloid cells.
  • Primary culture of mouse microglia and bone marrow-derived myeloid cells were activated with IL-4 (10 ng/ml), IFN- ⁇ (10 ng/ml), IL-IO (10 ng/ml) or in combination of interferon (IFN)- ⁇ +IL-4 or IL-10+IL-4 for 5 days.
  • IFN interferon
  • IL-10+IL-4 interferon- ⁇ +IL-4
  • IL-4 induces microglia to express CDl Ic and MHC-II, whereas IFN- ⁇ induces only MHC-II.
  • IL-IO has no effect on the expression, whereas IL-IO suppressed IL-4-induced MHC-II, but not CDl Ic expression.
  • 4B Similar pattern of activation was observed in mouse bone marrow-derived myeloid cells. Quantitative analysis of expression of CDl Ic and MHC-II (expressed as a percentage of IB-4-labeled microglia) in microglia (4C) and bone marrow-derived myeloid cells (BM) (4D).
  • Results are of three independent experiments in replicate cultures; bars represent means ⁇ SEM. Asterisks above bars denote the significance of differences relative to untreated cells (P ⁇ 0.05; ** P ⁇ 0.01; *** P ⁇ 0.001; two- tailed Student's t-test). The P values indicated in the figure represent a comparison of the groups as analyzed by ANOVA.
  • Fig. 5 shows that IL-4 induces expression of IGF-I and BDNF in bone marrow-derived myeloid cells. Bone marrow-derived myeloid cells were activated as described in Fig. 4. Confocal images represent immunocytochemistry for microglial marker IB4, IGF-I and BDNF. Untreated cells hardly express BDNF and IGF-I. No effect was found after IFN- ⁇ activation, whereas IL-10 significantly increases BDNF but not IGF-I. IL-4 alone or in a combination with IFN- ⁇ induces both IGF-I and BDNF. Addition of IL-IO together with IL-4 has a superior effect on induction of BDNF. Separate confocal channel is shown in right panel. Figs.
  • 6A-6B show that IFN- ⁇ , unlike IL-IO, induces microglial expression of ICAM-I .
  • Microglial culture described in Fig. 4 was analyzed for ICAM-I expression.
  • IFN- ⁇ significantly induces microglia to express ICAM- 1, whereas either IL-4 or IL- IO has no effect.
  • IL-4 does not affect IFN- ⁇ -induced ICAM-I
  • IL-IO significantly inhibited IFN- ⁇ -induced ICAM-I expression.
  • 6B Quantitative analysis of expression of ICAM- 1 [expressed as intensity per cell in arbitrary units (AU)].
  • Results are of three independent experiments in replicate cultures; bars represent means ⁇ SEM. Asterisks above bars denote the significance of differences relative to untreated cells (P ⁇ 0.05; ** P ⁇ 0.01 ; *** P ⁇ 0.001 ; two- tailed Student's t-test). The P values indicated in the figure represent a comparison of the groups as analyzed by ANOVA
  • Fig. 7 shows that in mice with chronic EAE, intraventricular Iy injected BM (IL-4) significantly improves clinical features and induces oligodendrogenesis.
  • Chronic EAE was induced in C57BL/6J mice.
  • EAE scores in mice injected with either non-activated (BM (-) ) or IL-4-activated (BM (IL-4) ) syngeneic bone marrow- derived myeloid cells of CX 1 CRl P Fm /CDl ic D TM-transgenic mice ⁇ n 7 in each group) at 9 days after MOG-vaccination.
  • Additional group of BM (IL-4) -treated mice received DT (BM (1L .
  • mice induced with EAE received the same regimen of DT (MOG /DT) and used as a control. Injection of
  • 8A Representative FACS analysis of healthy control and both GA-treated and untreated MS patients in remission phase.
  • Figs. 9A-9D demonstrate that IL-4 can counteract the adverse effect of aggregated A ⁇ on microglial toxicity and promotion of neurogenesis in adult mouse neural progenitor cells (NPC).
  • NPC neural progenitor cells
  • FIG. 9C Separate confocal images of NPCs co- expressing GFP and ⁇ lll-T adjacent to CDl Ib + microglia.
  • FIG. 9D Quantification of cells double-labeled with GFP and ⁇ lll-T (expressed as a percentage of GFP + cells) obtained from confocal images. Results are of three independent experiments in replicate cultures; bars represent means ⁇ SEM. Asterisks above bars denote the significance of differences relative to untreated (control) NPCs (P ⁇ 0.05; *** P ⁇ 0.001 ; two-tailed Student's t-test). Horizontal lines with P values above them show differences between the indicated groups (ANOVA).
  • Figs. 10A-10L show that Cop-1 vaccination leads to reduction in ⁇ -amyloid and counteracts loss of hippocampal neurons in the brains of transgenic Alzheimer's disease mice: key role of microglia.
  • Fig. 10A Representative confocal microscopic images of brain hippocampal slices from non-transgenic (non-Tg), untreated-Tg- Alzheimer' s disease (AD), and Cop-1 -vaccinated Tg-AD mice stained for NeuN (mature neurons) and human A ⁇ .
  • the non-Tg mouse shows no staining for human A ⁇ .
  • the untreated-Tg- AD mouse shows an abundance of extracellular A ⁇ plaques, whereas in the Cop-1 -treated Tg-AD mouse A ⁇ -immunoreactivity is low.
  • FIG. 10B Staining for activated microglia using anti-CD l ib antibodies. Images at low and high magnification show a high incidence of microglia double-stained for A ⁇ and CDl Ib in the CAl and dentate gyrus regions of the hippocampus of an untreated- Tg-AD mouse, but only a minor presence of CDl Ib + microglia in the Cop-1- vaccinated Tg-AD mouse.
  • FIG. 10C CDl Ib + microglia, associated with an A ⁇ plaque, strongly expressing TNF- ⁇ in an untreated-Tg-AD mouse.
  • FIG. 10D Staining for MHC-II (a marker of antigen presentation) in a cryosection taken from a Cop- 1 -vaccinated Tg-AD mouse in an area that stained positively for A ⁇ shows a high incidence of MHC-II + microglia and almost no TNF-Ct + microglia.
  • FIG. 10H are associated with MHC-II + microglia. Boxed area shows high magnification of an immunological synapse between a T cell (CD3 + ) and a microglial cell expressing MHC-II.
  • FIG. 101 Histogram showing the total number of A ⁇ -plaques (in a 30- ⁇ m hippocampal slice).
  • Fig. 10J Histogram showing staining for A ⁇ -immunoreactivity. Note the significant differences between Cop- 1 -vaccinated Tg-AD and untreated-Tg-AD mice, verifying the decreased presence of A ⁇ -plaques in the vaccinated mice.
  • FIG. 10K Histogram showing a marked reduction in cells stained for CDl Ib, indicative of activated microglia and inflammation, in the Cop- 1 -vaccinated Tg-AD mice relative to untreated-Tg-AD mice. Note the increase in CDl Ib + microglia with age in the non- Tg littermates.
  • FIG. 10L Histogram showing significantly more CD3 + cells associated with an A ⁇ -plaque in Cop- 1 -vaccinated Tg-AD mice than in untreated- Tg-AD mice. Quantification of CD3 + cells was analyzed from 30-50 plaques of each mouse tested in this study. Error bars indicate means ⁇ SEM.
  • Figs. 1 IA-11C show that Cop-1 vaccination induces microglia to express CDl Ic.
  • Fig. HA CDl Ib + microglia co-expressing CDl Ic surround an A ⁇ -plaque in Cop-1 -vaccinated transgenic Alzheimer (Tg-AD) mice. All of the CDl Ic- expressing microglia are co-labeled for CDl Ib. Separate confocal channel is shown in right panel.
  • Fig. HB Histograms showing the number of CDl Ib + cells associated with A ⁇ -plaque.
  • Fig. HC Histograms showing quantification of CDl Ic + cells as a percentage of the total number of CDl Ib + and CDl Ic + cells associated with an A ⁇ -plaque.
  • Figs. 12A-12D show that Cop-1 vaccination induces microglia (MG) to express CD l Ic: role of IL-4.
  • Fig. 12A IL-4-activated microglia (MG (IL-4) ) induce CD l Ic expression in a primary culture of mouse microglia 5 days after activation. Untreated microglia (MG H ) express hardly any CDl Ic.
  • Fig. 12B Effect of IL-4 (in terms of morphology and CDl Ic expression) on microglia pretreated for 3 days with aggregated A ⁇ ( i- 40) (MG (A ⁇ )) and assessed 10 days later compared to IL-4 treatment for 10 days without pre-exposure to A ⁇ .
  • FIG. 12C Quantitative analysis of microglial expression of CDl Ic + microglia (expressed as a percentage of IB-4-labeled microglia) and of CDl Ic intensity per cell, both expressed as a function of time in culture with or without IL- 4.
  • FIG. 4D Quantitative analysis of CDl Ic expression (calculated as a percentage of IB-4-labeled microglia) by the cultures shown in (Fig. 12B). Results are of three independent experiments in replicate cultures; bars represent means ⁇ SEM. Asterisks above bars denote the significance of differences relative to untreated microglia at each time point ( *** P ⁇ 0.001 ; two-tailed Student's Mest).
  • Figs. 13A-13B show engulfment of aggregated A ⁇ by activated microglia.
  • Microglia were treated with IL-4 (10 ng/ml) 24 h after seeding (MG (1L-4) ) or were left untreated for 48 h (MG (-) ).
  • the media were then replaced by a labeling medium (DMEM containing 10 mg/ml bovine serum albumin), and aggregated A ⁇ ( i- 40) was added (5 ⁇ g/ml) for 1 h. Following incubation the cultures were fixed and immunostained with antibodies directed to human A ⁇ and co-stained for microglia (IB-4).
  • Fig. 13A Confocal photomicrographs.
  • Fig. 13B Quantitative analysis expressed as intensity per cell. Results of one of two experiments, each containing eight replicates (20-30 cells per replicate) per group, are presented (means ⁇ SD).
  • Figs. 14A-14E depict enhanced neurogenesis induced by Cop-1 vaccination in the hippocampal dentate gyri of adult transgenic AD mice (Tg).
  • mice in each experimental group were injected i.p. with BrdU twice daily for 2.5 days.
  • mice in each experimental group were excised and the hippocampi analyzed for BrdU, DCX (a marker of early differentiation of the neuronal lineage), and NeuN (a marker of mature neurons).
  • Figs. 14A-14C Histograms showing quantification of the proliferating cells (BrdU + ).
  • Fig. 14A Newly formed mature neurons (BrdU + /NeuN + )
  • FIG. 14D Representative confocal microscopic images of the dentate gyrus showing immunostaining for BrdU/DCX/NeuN in a Cop-1 -vaccinated Tg-AD mouse and in a non-Tg littermate relative to that in an untreated-Tg-AD mouse.
  • FIG. 14E Branched DCX + cells are found near MHC-II + microglia located in the subgranular zone (SGZ) of the hippocampal dentate gyrus of a Cop- 1 -vaccinated Tg-AD mouse.
  • Fig. 16 is a photo of a new apparatus for pre-clinical research.
  • a Plexiglas plate two thick lead disks are held apart by short lead columns. Attached concentrically and level to the lower disk is a thin Plexiglas ring. Mice are placed on this surface with their heads between the disks. Two removable handles allow positioning the apparatus.
  • Figs. 17A-17C show that CX3CR1-GFP + bone marrow- derived microglia migrated into the brain after total body ⁇ -irradiation (Fig. 17A). High magnification of the cells are represented in Fig. 17B. (Fig. 17C) CX3CR1-GFP + microglia co- expressing MHC-II and IGF-I (separate channels of confocal image).
  • Fig. 18 shows CDl Ib + microglia co-expressing ICAM-I associated with A ⁇ - plaques in the hippocampus of Tg-AD mice at 12 months of age. Top pannels represent separate channels of immunohistochemistry for human A ⁇ (green), CDl Ib (blue) and ICAM-I (red).
  • Fig. 19 shows that CX3CR1-GFP + bone marrow-derived microglia migrated into diseased spinal cord of SODl -transgenic mice. Confocal microscopy immunohistochemistry for activated microglia labeled with CDl Ib (red) and CDl Ic (blue). Note, all CX3CR1-GFP + cells co-express CDl Ib. Fig.
  • Figs. 21A-21H show that microglia treated with IFN- ⁇ differentiated into neuronal-like cells.
  • 21A ln-vitro treatment paradigm.
  • 21B Representative confocal microscopic images of microglia stained for CDl Ib and ⁇ lll-tubulin ( ⁇ lll- T; neuronal marker), co-cultured for 10 days in microglial medium in the presence of IFN- ⁇ (lOng/ml) (MG 0FN- ⁇ ) ) or IL-4 (lOng/ml) (MG ( i L . 4) ).
  • IFN- ⁇ induced microglia to adopt a morphology of elongated cells co-expressing CDl lb/ ⁇ lll-T
  • IL-4-treated microglia exhibited a round-shape morphology as compared to untreated microglia (MG (-) ).
  • 21C, 21D Separate confocal images of ⁇ III-T + MG ( i FN - ⁇ ) co-expressing MHC-II (21c) and microglial marker isolectin B4 (IB4) (21D).
  • Figs. 22A-22C show time course of CDl Ic expression in microglia activated by IFN- ⁇ and IL-4.
  • Microglia were treated with IFN- ⁇ (10 ng/ml; MGp. ⁇ ) ) or IL-4 (10 ng/ml; MG (IL-4) ) for 1, 3, 5, 10 and 18 days as described in Fig. 21.
  • MG ( . ) Were used as controls.
  • MG (-) did not express CDl Ic.
  • Figs. 23A-23D show that ⁇ III-tubulin + elongated cells are derived from microglia.
  • 23A Confocal images represent primary culture of microglia from transgenic mice labeled for GFP under the promoter of the chemokine fractalkine receptor CX 3 CRl (CX 3 CRl GFP/+ ) and co-expressing doublecortin (DCX, a marker of early differentiation of the neuronal lineage) and ⁇ lll-T (neuronal marker) after 5 days of treatment with IFN- ⁇ (10ng/ml). Arrows represent the co-expression and elongated morphology of the cells in separate confocal images.
  • 23B In-vitro treatment paradigm.
  • Figs. 24A-24F show that microglia exhibit stem-like features.
  • Figs. 25A-25B show that IL-4, unlike IFN- ⁇ , increased expression of glial markers without inducing morphological features.
  • 25A Representative confocal images Of GFP + microglia from CX 3 CRl CF/y+ -transgenic mice treated with IL-4 (10 ng/ml) and IFN- ⁇ (10 ng/ml) for 10 days and stained for glial fibrillary acidic protein (GFAP, a marker for glial cells).
  • GFAP glial fibrillary acidic protein
  • IL-4 unlike IFN- ⁇ triggered expression of GFAP without inducing morphological features of astrocytes.
  • 25B IL-4 increased the expression of proteoglycan oligodendrocytes marker NG2.
  • Fig. 26 shows microglia after long time exposusre to high levels (100ng/ml) of IFN- ⁇ (MG ( i FN ⁇ -ioo ng) ) 5 low levels of IFN- ⁇ (MG (1FN ⁇ ) ), IL-4 (MG (IL-4) ), and/or LPS MG(LP 5 ).
  • Figs. 27A-27B show that expression of danger signals in SOD1 G93A mice is delayed relative to disease (ALS) progression.
  • SOD 1 G93 ⁇ and control mice were killed at different stages of clinical manifestation of ALS: pre-disease onset (60 d); disease onset (90 d); and disease progression (120 d).
  • ICAM-I, CDl Ib, and CDl Ic expression in lumbar spinal cord regions were analyzed by immunohistochemistry. Representative confocal images of lumbar spinal cord areas are presented.
  • (27B) expression of CDl Ic The relevant high-power micrographs are shown below the panels indicating boxed areas.
  • Figs. 28A-H show that dendritic-like BM-derived myeloid cells expressing IGF-I home to spinal cords in ALS mice.
  • Spinal cords of chimeric- and untreated- S ODl were analyzed for GFP, CDl Ib, and CDl Ic (28A, 28B and 28E, 28F, respectively), and for IGF-I (28C, 28D and 28G, 28H, respectively).
  • Figs. 29 A-B show that BM (IL-4) cells from wild-type mice injected systemically into SOD1 G93A diseased mice are recruited exclusively into the ventral horn of the spinal cord.
  • IL-4-activated BM-derived myeloid cells from CX3CR1 GFP - transgenic mice were injected i.v. into SOD1 G93A mice at the stage of progressive disease (at ages 125 days, 130 days, and 136 days). At end stage (approximately 140 days) the mice were killed, and their spinal cords were analyzed for GFP + cells and co-stained for CDl Ib, CDl Ic (29A), and IGF-I (29B).
  • Figs. 30A-B show that IL-4 induces CDl Ic and IGF-I expression in BM- derived myeloid cells of both SOD and wild-type (WT) mice.
  • Myeloid cells were isolated from BM and treated with IL-4 ( 10 ng/ml) for 72 h. Untreated cells were used as controls.
  • Cells were analyzed by immunocytochemistry for expression of CDl Ic (30A) and IGF-I (30B). No differences were observed in the BM cells derived from SOD and WT mice (three independent experiments, each carried out in triplicate).
  • Q-PCR of BM-derived myeloid cells as described in 3OA, 48 hours after treatment.
  • the present invention relates to a method for promoting body tissue repair in an individual, said method comprising administering to the individual in need a therapeutically effective amount of CDl Ic + bone marrow- derived myeloid cells.
  • the present invention relates to a method for promoting tissue repair in an individual in need, which comprises mobilizing CDl Ic + bone marrow-derived myeloid cells to the damaged tissue of said individual.
  • the CDl Ic + bone marrow-derived myeloid cells for use in the methods of the invention may be obtained by activation with at least one cytokine selected from IL-4, IL- 13 or a narrow concentration range of IFN- ⁇ of up to 20 ng/ml.
  • the CDl I c + bone marrow-derived myeloid cells particularly those activated by IL-4, also express IGF-I, BDNF or both IGF-I and BDNF.
  • the present invention also relates to a method for promoting tissue repair in a patient, said method comprising administering to the patient a therapeutically effective amount of bone marrow-derived myeloid cells that have been activated with a cytokine selected from IL-4, IL- 13 or a narrow concentration range of IFN- ⁇ of up to 20 ng/ml.
  • a cytokine selected from IL-4, IL- 13 or a narrow concentration range of IFN- ⁇ of up to 20 ng/ml.
  • the method of the invention comprises administering to an individual in need IL-4 activated bone marrow-derived myeloid cells.
  • the CDl Ic + cells may be
  • CDl lb + /CDl lc + cells particularly, CDl lb + /CDl lc + /MHC-lf microglia, a phenotype induced by IL-4.
  • IL-4 has often been described as an anti-inflammatory cytokine (Chao et al., 1993).
  • our results herein strongly argue against this perception and show instead that IL-4 activates microglia to adopt a phenotype that seems to acquire a different morphology and a different activity from those of the innately activated microglia or of the activated microglia commonly seen in neurodegenerative diseases such as Alzheimer's disease (AD) or multiple sclerosis (MS).
  • AD Alzheimer's disease
  • MS multiple sclerosis
  • the microglia appear to be overwhelmed by an onslaught of adaptive immunity (Butovsky et al., 2006a).
  • IL-4 is capable of restoring a favorable activated phenotype even after the microglia have already exhibited phenotypic characteristics of aggregated A ⁇ ((Butovsky et al, 2005 and shown herein) or been overwhelmed by IFN- ⁇ (Butovsky et al., 2006a).
  • IL- 13 has the same effect as IL-4, because it is well established in the field of cytokines that IL-4 and IL- 13 can utilize a common receptor and share many actions such as B-cell activation and suppression of Th-I cells.
  • ICAM-I intracellular adhesion molecule- 1
  • LFA-I CDl la/CD18
  • Mac-1 CDl lb/CD18
  • CDl lc/CDl ⁇ integrins belonging to the ⁇ 2 subfamily i.e., CDl la/CD18 (LFA-I), CDl lb/CD18 (Mac-1), and CDl lc/CDl ⁇ .
  • ICAM-I adhesive interactions are critical for the transendothelial migration of leukocytes and the activation of T cells where ICAM- 1 binding functions as a co-activation signal.
  • ICAM-I is present constitutively on the cell surface of a wide variety of cell types including fibroblasts, leukocytes, keratinocytes, endothelial cells, and epithelial cells, and is upregulated in response to a number of inflammatory mediators, including retinoic acid, virus infection, oxidant stresses such as H 2 O 2 , and the proinflammatory cytokines, IL- l ⁇ , TNF- ⁇ , and IFN- ⁇ .
  • inflammatory mediators including retinoic acid, virus infection, oxidant stresses such as H 2 O 2 , and the proinflammatory cytokines, IL- l ⁇ , TNF- ⁇ , and IFN- ⁇ .
  • the CDI l + bone marrow-derived myeloid cells subject of the instant invention home to the damaged tissue due to the interaction between the CDl Ic expressed on their surface and ICAM- 1 expressed in cells in distressed tissue. Since ICAM-I is upregulated in most cell types in response to extracellular stress, any damaged body tissue can be repaired by the CDl I + bone marrow-derived myeloid cells of the invention. Examples of these body tissues include, but are not limited to, neural tissue, cardiac tissue, liver tissue, renal tissue, bladder tissue, muscle tissue, intestinal tissue, or visual system tissue.
  • CNS disorders and diseases are caused by damage to the CNS, which is exacerbated by secondary degeneration.
  • CNS disorders and diseases are manifestations of damage inflicted on the CNS tissue, no matter what was the primary cause of the damage.
  • the CDI l + bone marrow- derived myeloid cells for example, obtained by activation with a cytokine selected from IL- 4, IL- 13 or up to 20 ng/ml IFN- ⁇ , infiltrate damaged brain tissue and thus can be used to repair brain tissue damage associated with a range of CNS diseases or disorders.
  • a cytokine selected from IL- 4, IL- 13 or up to 20 ng/ml IFN- ⁇
  • the CDI l + bone marrow-derived myeloid cells of the invention are used for treatment of neurodegenerative diseases or disorders including, but not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis (ALS), mental disorders, neuropathies, cognitive dysfunction, dementia, the aging process and senescence.
  • the cells are used for treatment of injuries in the brain or in the spinal cord.
  • the methods of the invention are also useful for treatment of ischemia, particularly in tissues especially sensitive to inadequate blood supply such as the heart, the kidneys and the brain.
  • Ischemia in brain tissue for example due to a cerebrovascular accident such as stroke or head injury, may ultimately kill brain tissue leading to permanent neurologic damage or even death.
  • Ischemia in the heart leads to myocardial infarction or heart attack.
  • the mental disorders that can be treated by the methods of the invention include psychiatric disorders selected from: (i) anxiety disorders, that include phobic disorders, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder; (ii) mood disorders, that include depression, dysthymic disorder, bipolar disorders and cyclothymic disorder; (iii) schizophrenia and related disorders such as brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; (iv) drug use and dependence such as alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and (v) memory loss disorders such as amnesia or memory loss associated with Alzheimer's type dementia or with non- Alzheimer's type dementia, e.g. multi-infarct dementia or memory loss associated with Parkinson's disease, Huntington's disease, Creutzfeld- Jakob disease, head trauma, HIV infection, hypothyroidis
  • the activated bone marrow-derived myeloid cells of the invention are used for treatment of cardiovascular diseases, particularly heart diseases such as myocardial infarction, ischemic heart disease and congestive heart failure (CHF), as known in cellular therapy for such diseases.
  • cardiovascular diseases particularly heart diseases such as myocardial infarction, ischemic heart disease and congestive heart failure (CHF)
  • heart diseases such as myocardial infarction, ischemic heart disease and congestive heart failure (CHF)
  • CHF congestive heart failure
  • these heart diseases remain the major causes of morbidity and mortality in the westen countries.
  • Cellular therapy for treating these and other heart conditions is a growing field of clinical research.
  • the activated bone marrow-derived myeloid cells of the invention can be used for promoting tissue repair in a patient suffering from an autoimmune disease.
  • the cells for use in the present invention are preferably autologous, namely, they are obtained from peripheral blood or bone marrow of the individual to be treated.
  • allogeneic cells from an HLA-matched donor can be used.
  • the cells are obtained from peripheral blood or bone marrow of the individual or donor and processed by techniques well known in the art. .
  • the myeloid cells may be cultured until they multiply to the level needed for transplantation into the patient and are then activated with at least one cytokine selected from IL-4, IL- 13 and up to 20 ng/ml IFN- ⁇ for the time necessary to upregulate CDl Ic expression.
  • at least one cytokine selected from IL-4, IL- 13 and up to 20 ng/ml IFN- ⁇ for the time necessary to upregulate CDl Ic expression.
  • activation with up to 20 ng/ml IFN- ⁇ may take 2-3 days until the peak of CDl Ic expression is reached.
  • the invention relates to a process for the preparation of a cellular preparation comprising CDl Ic + bone marrow-derived myeloid cells which comprises obtaining myeloid cells from the peripheral blood or from the bone marrow of an individual, and culturing the cells with at least one cytokine selected from IL-4, IL- 13 and up to 20 ng/ml IFN- ⁇ for the time necessary to upregulate CD 1 1 c expression.
  • the cells Prior or after the culture with the cytokine, the cells can be purified by known techniques, for example using a magnetic bead system (e.g., from Miltenyi Biotec, Auburn, CA) and determining the purity.
  • the purity of cell cultures is monitored by flow cytometry using monoclonal antibodies (mAbs) directed to human CDl Ic.
  • mAbs monoclonal antibodies directed to human CDl Ic.
  • the cells are labeled by challenging with a commercially available fluorochrome-conjugated mAb, and then washed with PBS.
  • the fraction of cells positive for CDl Ic is regarded as a measure of culture purity.
  • the parameter is assayed both before and after the incubation/activation stage.
  • the purity of the cell culture should be >80%, preferably 90% , 97% or more CDl Ic + cells.
  • microglia are immune cells of the CNS that are derived from myeloid progenitor cells, which come from the bone marrow. Thus, microglia are the resident CNS cells whereas the bone marrow-derived myeloid cells are the infiltrating cells. The resident microglia express ICAM-I during distress, and the bone marrow-derived infiltrating myeloid cellssexpress CDl Ic, which enables them to home to the immunological niche defined by the ICAM-I expressing cells.
  • the invention in another aspect, relates to a method for detecting and localizing a damaged tissue comprising administering bone marrow- derived myeloid cells that have been activated with at least one cytokine selected from IL-4, IL- 13 or up to 20 ng/ml IFN- ⁇ and are labeled with an imaging agent to an individual having or suspected of having a damaged tissue, whereby the labeled cells traffic to the damaged tissue, and imaging the suspected tissue area in the individual, thereby detecting and localizing the damaged tissue.
  • cytokine selected from IL-4, IL- 13 or up to 20 ng/ml IFN- ⁇
  • the cells can be labeled with any agent that allows imaging by any of the imaging techniques.
  • the cells can be detectably labeled with a contrast agent including, without limitation, metals such as gold particles, gadolinium complexes, etc.
  • the cells can be labeled detectably with a radioisotope, including but not limited to 125 Iodine, Ijl Iodine, 99m-Technecium.
  • the cells can also be detectably labeled using a fluorescence emitting metal such as 152 Eu, or others of the lanthanide series.
  • imaging agents are contrast agents suitable for magnetic resonance imaging (MRI) such as, but not limited to, diamagnetic agents useful in gastrointestinal imaging, paramagnetic agents such as ions of the metals Gd (preferably gadolinium chelates such as Gd-DTPA), Fe, Mg and Dy, or superparamagnetic and ferromagnetic agents.
  • Other labeling agents are contrast agents for positron emission tomography (PET) or for functional MRI (fMRI).
  • Labeling of the cells with metal particles may be achieved by incubating cells in a suspension comprising the metal particles wherein the cells spontaneously internalize such particles into the cell's cytosol.
  • Such substances may also be introduced into the cells by a variety of electroporetic techniques (Current Protocols in Immunology, 1997, Eds. Coligan et al., John Wiley & Sons, Inc., NIH). Fluorescence emitting metals or radioactive metals can be attached to the cells using such metal chelating agents as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). Labeling of the cells with a radioisotope can be achieved by incubating cells with a radioactive metabolic precursor.
  • DTPA diethylenetriaminepentacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • CT computed tomography
  • PET position emission tomography
  • MRI magnetic resonance imaging
  • sonography radiation responsive surgical instrument
  • the present invention relates to a method for delivering a therapeutic or detectable substance to a damaged tissue or a tumor, said method comprising administering to a patient in need bone marrow-derived myeloid cells that have been activated with at least one cytokine selected from IL-4, IL- 13 or up to 20 ng/ml IFN- ⁇ , wherein said cells are cells that have been genetically engineered to express said therapeutic or detectable substance.
  • the present invention is thus directed to methods for the treatment or diagnosis of damaged tissues or tumors by delivering a therapeutic or detectable substance to a damaged site or to the tumor, comprising administering an effective amount of bone marrow-derived myeloid cells that have been activated with at least one cytokine selected from IL-4, IL- 13 or up to 20 ng/ml IFN- ⁇ , said cells expressing a therapeutic or detectable substance, to an individual in need wherein the amount is effective to detect, diagnose, or monitor a site of injury or disease or a tumor in the body or is effective to ameliorate the effects of an injury or disease or to treat the tumor.
  • compositions comprising the activated cells are used for delivery of (a) a diagnostic substance or (b) a therapeutic substance to a site of injury or disease of the body or to a tumor.
  • the cells may be genetically engineered in vitro to insert therein a nucleotide sequence encoding a polypeptide that can be used for terapy or diagnosis, by methods well known in the art.
  • the nucleotide sequence is under the control of necessary elements for transcription and translation such that a biologically active protein encoded by the nucleotide sequence can be either expressed continuously or induced to expression as a result of exposure of the cells to a microenvironment of a kind present at the damaged site. Due to the inherent degeneracy of the genetic code, other nucleotide sequences that encode substantially the same or a functionally equivalent amino acid sequence of a protein, are within the scope of the invention.
  • the expression product of said nucleotide sequence is a secretory protein.
  • the recombinant cells which contain a coding sequence and which express a biologically active gene product may be identified by at least four general approaches: (a) DNA-DNA or DNA-RNA hybridization; (b) the presence or absence of "marker" gene functions; (c) assessing the level of transcription as measured by the expression of mRNA transcripts in the cell; and (d) detection of the product encoded by the nucleotide sequence as measured by immunoassay or by its biological activity.
  • the presence of the coding sequence inserted in the expression vector can be detected by DNA-DNA or DNA-RNA hybridization using probes comprising nucleotide sequences that are homologous to the coding sequence or portions or derivatives thereof.
  • the recombinant expression system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, resistance to methotrexate, transformation phenotype, occlusion body formation in baculovirus, etc.).
  • telomere sequence can be assessed by hybridization assays. For example, RNA can be isolated and analyzed by Northern blot using a probe having sequence homology to a coding sequence or transcribed noncoding sequence or particular portions thereof.
  • total nucleic acid of the host cell may be extracted and quantitatively assayed for hybridization to such probes.
  • the levels of a protein product can be assessed immunologically, for example by Western blots, immunoassays such as radioimmuno-precipitation, enzyme-linked immunoassays and the like.
  • the cells may be stably transfected with said nucleotide sequences or may be transiently transfected. Transient transfection may be applicable for acute one-dose therapeutic regimens.
  • the nucleotide sequences inserted into the cells may encode various substances including, without limitation, therapeutic substances; enzymes which catalyze a therapeutic substance; a regulatory product which stimulates expression of a therapeutic substance in the cells, etc.
  • the nucleotides may be, for example: nucleotide sequences encoding neurotrophic factors such as NGF; nucleotide sequences encoding enzymes which play a role in CNS nerve regeneration such as the enzyme transglutaminase; nucleotide sequences encoding enzymes which catalyze the production of a neurotransmitter, e.g. enzymes involved in the catalysis of acetylcholine or dopamine, etc.
  • the cells which localize at the site of CNS injury or disease produce and secrete the needed substances at the site.
  • the nucleotide sequence When used for treatment or diagnosis of a tumor, the nucleotide sequence will encode a polypeptide that can treat or detect/localize the tumor, respectively.
  • the present invention relates to a method for monitoring the response of a patient being treated for a neurodegenerative or autoimmune disease or disorder to a therapeutic drug for said disease or disorder, said method comprising: (a) determining the level of CDl Ic + myeloid cells in a first sample of peripheral blood taken from the patient prior to treatment with the therapeutic drug; (b) determining the level of the CDl Ic + myeloid cells in at least one blood sample taken from the patient subsequent to the initial treatment with the therapeutic drug; and c) comparing the level of the CDl Ic + myeloid cells in the at least one blood sample of (b) with the level of the CDl Ic + myeloid cells in the first blood sample of (a); wherein an increase in the level of the CDl Ic + myeloid cells in the at least one blood sample of (b) compared to the level of the CDl Ic + myeloid cells in the first blood sample of (a), indicates that the therapeutic drug is effective in treating said neurodegenerative or autoimmune disease or disorder in said patient
  • the method monitors a patient being treated for a neurodegenerative disease or disorder such as, but not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, age-related macular degeneration, neuropathies, mental disorders, cognitive dysfunction, dementia, and prion diseases.
  • a neurodegenerative disease or disorder such as, but not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, age-related macular degeneration, neuropathies, mental disorders, cognitive dysfunction, dementia, and prion diseases.
  • the neurodegenerative disease is multiple sclerosis.
  • the method monitors a patient being treated for an autoimmune disease or disorder such as, but not limited to, Eaton-Lambert syndrome, Goodpasture's syndrome, Grave's disease, Guillain-Barre syndrome, autoimmune hemolytic anemia (AIHA), hepatitis, insulin-dependent diabetes mellitus (IDDM), systemic lupus erythematosus (SLE), myasthenia gravis, plexus disorders e.g. acute brachial neuritis, polyglandular deficiency syndrome, primary biliary cirrhosis, rheumatoid arthritis, scleroderma, thrombocytopenia, thyroiditis e.g.
  • an autoimmune disease or disorder such as, but not limited to, Eaton-Lambert syndrome, Goodpasture's syndrome, Grave's disease, Guillain-Barre syndrome, autoimmune hemolytic anemia (AIHA), hepatitis, insulin-dependent diabetes mellitus (IDDM), systemic
  • Hashimoto's disease Sjogren's syndrome, allergic purpura, psoriasis, mixed connective tissue disease, polymyositis, dermatomyositis, vasculitis, polyarteritis nodosa, polymyalgia rheumatica, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, pemphigus, bullous pemphigoid, dermatitis herpetiformis, inflammatory bowel disease (IBD; e.g. Crohn's disease) and uveitis.
  • IBD inflammatory bowel disease
  • the level of CDl Ic + myeloid cells in samples of peripheral blood of individuals with symptoms consistent with neurodegenerative or autoimmune diseases and suspected of having a neurodegenerative or autoimmune disease is measured and compared with the "normal" level of these cells as established in sample(s) from one or more individuals not having neurodegenerative or autoimmune diseases.
  • Low levels of the CDl Ic + myeloid cells in a sample from an individual with suspected neurodegenerative or autoimmune disease relative to the "normal" level is indicative of said individual having a neurodegenerative or autoimmune disease, while similar levels relative to the "normal” level indicate an absence of such a disease.
  • the invention further relates to a method for monitoring transition between periods of remission and relapse in relapsing/remitting multiple sclerosis in a patient, comprising:
  • the method above will permit treatment of the patient close to the period of relapse in an attempt to revert the situation and bring the patient again to the remission period.
  • the invention further relates to a method for the diagnosis and follow up of a neurodegenerative or autoimmune disease or disorder in an individual, comprising:
  • the present invention provides a cellular preparation comprising CDl Ic + bone marrow-derived myeloid cells and a physiologically acceptable carrier, for promoting repair of damaged body tissue.
  • the cellular preparation comprises CDl Ic + bone marrow-derived myeloid cells that express IGF-I, BDNF or both.
  • the CDl Ic + bone marrow- derived myeloid cells express IGF-I.
  • the CDl Ic + bone marrow-derived myeloid cells are obtained by activation of bone marrow-derived myeloid cells with at least one cytokine selected from the froup consisting of IL-4, IL- 13 and up to 20 ng/ml IFN- ⁇ , more preferably IL-4 or a a mixture of IL-4 and up to 20 ng/ml IFN- ⁇ .
  • the cellular therapy composition comprises the cells suspended in a physiologically/pharmaceutically acceptable carrier such as PBS or, preferably, in a culture medium such as IMDM or any other suitable cell culture medium such as
  • the activated cells of the invention can be administered by any suitable route used in cellular therapy, for example, systemic infusion, local arterial infusion, venous infusion or they can be administered in situ by direct injection into the damaged tissue, e.g. at the infarct site or at or near a site of injury of the CNS.
  • the cellular preparation is administered intravenously.
  • the invention provides a cellular preparation for detection and localization of damaged body tissue, comprising bone marrow- derived myeloid cells that have been activated with at least one cytokine selected from the group consisting of IL-4, IL- 13 and up to 20 ng/ml IFN- ⁇ and labeled with an imaging agent.
  • Copolymer 1 which commercial form is also known as glatiramer acetate, is used in the examples.
  • the terms "Cop 1”, “Copolymer 1”, “glatiramer acetate” and “GA” are used interchangeably in the examples.
  • MS Multiple sclerosis
  • inflammation within the CNS blocks neurogenesis (Monje et al., 2003; Ekdahl et al., 2003) and causes structural damage to myelin (Hartung et al., 1992; Olsson, 1995).
  • inflammation-associated microglia impeded both neurogenesis and oligodendrogenesis from adult stem cells (Butovsky et al., 2006a, 2006b, 2006c).
  • ThI and Th2 cells recognizing CNS antigens are needed for CNS maintenance and repair.
  • the need for a specific subtype, its intensity and duration are determined by the type of the damaged conditions (acute or chronic), and the amount of time transpired following the insult in the case of acute conditions.
  • whether or not the T cells are beneficial is determined by their dose.
  • One of the main targets of the T-cell effect was found to be the microglia (Butovsky et al., 2006a, 2006b, 2006c, 2005; Shaked et al., 2005).
  • microglia exposed to low concentrations of IFN- ⁇ exhibit an immune-mediated healing response
  • microglia exposed to high IFN- ⁇ concentrations are associated with an immune-mediated demyelinating disease (Hartung et al., 1992; Olsson, 1995; Butovsky et al., 2006a)
  • microglia exposed to IL-4 over a wide range of concentrations, can support neuronal survival (Butovsky et al, 2005).
  • IL- 4 via modulation of microglia both in vitro and in vivo, can overcome the destructive effects of high-dose IFN- ⁇ .
  • IL-4 In vitro, a high dose of IFN- ⁇ , but not a low dose, impairs the ability of microglia to support oligodendrogenesis from adult neural stem cells/progenitor cells (NPCs), and IL-4 counteracts the interference with oligodendrogenesis.
  • IL-4-activated microglia were stereotaxically injected through the cerebral ventricles into the cerebrospinal fluid (CSF) of rats with acute experimental autoimmune encephalomyelitis (EAE) or of mice with a remitting-relapsing autoimmune disease, the animals demonstrated significantly more oligodendrogenesis and significantly less neurological deficit than did their vehicle-injected diseased controls (Butovsky et al., 2006a).
  • IL-4 can reverse the destructive effect of overwhelmed activated microglia (MG), known to be associated with MS.
  • MG activated microglia
  • therapeutic immunomodulation with GA known to be beneficial in MS, induces oligodendrogenesis in EAE mice.
  • GA dendritic-like MG
  • CDl Ic reminiscence of IL-4-activated MG dendritic-like MG
  • GFP green fluorescent protein gene
  • DTR Diphtheria toxin receptor
  • the cell-proliferation marker BrdU was dissolved by sonication in PBS and injected i.p. (50 mg/kg body weight) every 12 hours for 2.5 days, starting on day 19 after MOG vaccination in adult male C57BL/6J mice.
  • i.p. 50 mg/kg body weight
  • the animals were deeply anesthetized and perfused transcardially, first with PBS and then with 4% paraformaldehyde.
  • Their spinal cords were removed, postfixed overnight, and then equilibrated in phosphate-buffered 30% sucrose. Free- floating 30- ⁇ m longitudinal sections were collected on a freezing microtome (Leica SM2000R) and stored at 4°C prior to immunohistochemistry.
  • the tissue was then stained with rat anti-BrdU (1 :200; Oxford Biotechnology) in combination with rabbit anti-NG2 (1 :300) and mouse anti-RIP (1 : 1000) antibodies diluted in PBS containing 0.05% Triton XlOO, 0.1% Tween 20, and 2% horse serum.
  • IB4 1 :50
  • mouse anti MHC-II Abs 1 :50; IQ Products
  • Expression of IGF-I was detected by goat anti IGF-I Abs (1 : 10-1 : 100; R&D Systems).
  • Sections were incubated with the primary antibody for 24 hours at 4°C, washed with PBS, and incubated with the secondary antibodies in PBS for 1 hour at room temperature while protected from light.
  • Secondary antibodies used for both immunocytochemistry and immunohistochemistry were Cy-3 -conjugated donkey anti-mouse, Cy-3 -conjugated goat anti-rabbit, Cy-5-conjugated goat anti-rat, Cy-2- conjugated goat anti-rat, and Cy-5-conjugated donkey anti-goat. All antibodies were purchased from Jackson ImmunoResearch Laboratories and used at a dilution of 1 :250-500. Control sections (not treated with primary antibody) were used to distinguish specific staining from staining of nonspecific antibodies or autofluorescent components. Sections were then washed with PBS and coverslipped in polyvinyl alcohol with diazabicylo-octane as anti-fading agent.
  • Example 1 GA induces oligodendrogenesis from endogenous neural stem/progenitor cells in a chronic EAE model
  • ThI cell-mediated autoimmunity leads to chronic conditions of demyelization, known as autoimmune encephalomyelitis (Hartung et al., 1992; Olsson, 1992).
  • IL-4-activated MG injected into the CSF of animals with chronic EAE, promoted oligodendrogenesis from endogenous adult NPCs (Butovsky et al., 2006a).
  • GA is an immunomodulator FDA-approved for treatment MS. We therefore examined whether GA treatment of animals, in which EAE was induced, would promote oligodendrogenesis as well.
  • EAE was induced in C57BL/6J mice by immunization with the encephalitogenic MOG peptide (35-55) emulsified in IFA containing Mycobacterium tuberculosis and pertussis toxin (Butovsky et al., 2006a).
  • mice Eighteen days after MOG-vaccination, all mice were injected intraperitoneally (ip) with BrdU every 12 hours for 2.5 days to identify proliferating cells, and 7 days after the last BrdU injection their spinal cords were examined for the appearance of newly formed oligodendrocytes (Fig. 1).
  • the two groups of MOG- vaccinated mice differed significantly in the numbers of newly formed microglia and oligodendrocytes as compared to na ⁇ ve mice.
  • EAE was associated with increased BrdU + and BrdlT7lB4 + (proliferating microglia) cells which was further increased by the treatment with GA (Fig. IA).
  • the CDl Ic found in the spinal cord of GA-immunized animals could be either resident MG that were activated locally by T cell-derived cytokines or recruited bone marrow-derived myeloid cells that were activated peripherally by T cell-derived cytokines. It has been suggested that MG are replenished partly by division of resident cells and partly by immigration of circulating monocytes (Lawson et al., 1992). Moreover, in lethally irradiated mice transplanted with BM cells expressing GFP, the cells immigrated into the brain parenchyma of many regions of the CNS.
  • CDl Ic + cells derived from BM recruited to the site of damage needed to fight off the adverse conditions we created chimera mice with BM cells derived from double transgenic mouse model CX 3 CR 1 GFP /CD Uc DTR that express GFP under the promoter of the chemokine fractalkine receptor CX 3 CRl (Jung et al., 2000) and DTR (diphtheria toxin receptor) under CDl Ic promoter (Jung et al., 2002).
  • heterozygous mice (CX 3 CR1 GFP+ ) express both the DTR and GFP on peripheral monocytes and on a subset of mononuclear phagocytes that include macrophages and dendritic cells (Davalos et al;, 2005, Geissmann et al., 2003).
  • EAE was induced in the chimera mice by immunization with MOG, as described above.
  • MOG MOG
  • DT diphtheria toxin
  • IL-4 renders both microglia and bone marrow-derived myeloid cells a dendritic-like phenotype which produces IGF-I and BDNF
  • cytokines associated with induction of CDl Ic we analyzed the correlation between bone marrow-derived myeloid cells and brain derived microglia with three key cytokines: IFN- ⁇ , ThI -derived; IL-4, Th2 derived, and IL-IO, known to be associated with regulatory T cells. Both microglia and bone marrow-derived myeloid cells were treated for 5 days with IL-4 (10 ng/ml), IFN- ⁇ (100 ng/ml) or IL-IO (10 ng/ml), or combinations of IL-4 with IFN- ⁇ or IL-10. Low dose of IFN- ⁇ (10ng/ml) induced CDl Ic with a peak intensity at 2-3 days (data not shown).
  • IL-IO at low dose did not induce IGF-I and induced only a low level of BDNF, yet the combination of both IL-4 and of IL- 10 at a low level resulted in a synergistic increase with respect of BDNF expression (Fig. 5).
  • CDl Ic may play a role as an adhesion molecule which binds to receptors on stimulated epithelium. It associates with CDl 8 to form CDl lc/CD18 complex and binds to ICAM- I (Stacker & Springer, 1991; Frick et al., 2005). Increased expression of ICAM-I and CDl Ib correlated with the disease progression in an animal model of ALS (Alexianu et al., 2001) and AD (Apelt et al., 2002). ICAM-I upregulation in the spinal cords of mice with EAE is dependent upon TNF- ⁇ production (Scott et al., 2004).
  • Microglia activated with IFN- ⁇ produce TNF- ⁇ in dose dependent manner and have a detrimental effect on neural cell survival (Butovsky et al, 2005) and renewal (Butovsky et al., 2006a).
  • IL-4 and IL-10 the cytokine of Th2 cells induced by GA-vaccination (Duda et al., 2000, Vieira et al., 2003), were unable to induce ICAM-I .
  • IL-10 (10 ng/ml), unlike IL-4, significantly reduced IFN- ⁇ -induced ICAM-I expression (Figs. 6A, 6B).
  • IL- 10 at the concentration of 100 ng/ml completely blocked ICAM-I when added together with IFN- ⁇ (10 ng/ml; data not shown).
  • GA directly induced either microglia or bone marrow- derived cells to express ICAM- 1.
  • IL-4-activated microglia promote oligodendrogenesis in close association with MHC-II expressing microglia.
  • IGF-I that is produced by IL-4-activated microglia is responsible, at least in part, for the increased oligodendrogenesis (Butovsky et al., 2006a).
  • microglia as a result of the GA treatment, express a phenotype that is characteristic of dendritic cells.
  • CNS parenchyma can be populated by bone marrow cells.
  • An independent study showed that GA can regulate DC cells.
  • EAE or MS patients benefit from GA is by changing BM- derived myeloid cells which in turn reach the brain parenchyma. It was shown that GA reduces lymphocytes proliferation in MS patients by modulating monocyte- derived dendritic cells (Sanna et al., 2006).
  • microglia are originated from the bone marrow (Simard & Rivest, 2004). Under pathological conditions bone marrow-derived microglia can benefit the diseased brain in the case of AD (Simard et al., 2006). Therefore the GA-induced dendritic-like microglia found in the brain in the present work could be a result of a local effect of GA-activated T cells that homed to the EAE brain and via their secreted cytokine activated microglia to become dendritic- like cells. Alternatively, the GA treatment could cause enhanced recruitment of bone marrow-derived microglia expressing dendritic-like phenotype.
  • the systemic rise in the DC-activated bone marrow-derived cells could be a result of cytokine or direct GA activation (Sanna et al., 2006; Weber et al., 2004; Kim et al., 2004). Which ever is the mechanism, the present results suggest that the diminished plaques seen in MS patients treated with GA could be an outcome, at least in part of oligodendrocyte renewal.
  • IL-IO commonly viewed as an anti-inflammatory cytokine completely shut off MHC-II and CDl Ic expression.
  • IL-4-activated BM can deliver both BDNF and IGF-I.
  • IL- 10-activated BM can deliver BDNF but not IGF-I.
  • BM activated by the two cytokines can deliver both growth factors. It is thus suggestive that vaccination therapy with GA or any other antigen should be carefully designed when the choice of the regimen is made. Different regimen may differently affect the cytokines and the resulted systemic DC and the resident microglia.
  • the present study proposes that active vaccination by weak agonist of CNS antigen via bone marrow-derived myeloid cells, or by direct injection of IL-4-activated myeloid cells, it is possible to arrest uncontrolled inflammatory conditions in the CNS. Also emerging from the present study is that the phenotype of the myeloid cells homing to the brain critically determine disease resolution. This may be applicable to other CNS disease conditions, even noninflammatory; when distress signals are expressed and a local immune niche is created, systemic supply of IL-4-activated BM cells may be a way to arrest disease conditions. SECTION II
  • AD Alzheimer's disease
  • a ⁇ amyloid ⁇ -peptide
  • AD Alzheimer patients, like in transgenic (PDGF-APPSw, Ind) mice, some increase in neurogenesis takes place but is apparently not sufficient to overcome the disease (Jin et al., 2004a, Jin et al., 2004b). The primary cause of AD remains unknown (Akiyama et al., 2000).
  • microglia activated by aggregated A ⁇ is similar to that activated by lipopolysaccharide (LPS); microglia activated by LPS can act as phagocytes in removal of A ⁇ -plaques (DiCarlo et al., 2001).
  • LPS lipopolysaccharide
  • microglia activated by LPS can act as phagocytes in removal of A ⁇ -plaques.
  • a recent study by our group suggested that microglia exposed to aggregated Ap (I- ⁇ 0), although effective in removing plaques, are toxic to neurons and impair neural cell renewal; these effects are reminiscent of the response of microglia to invading microorganisms (as exemplified by their response to LPS) (Butovsky et al, 2005, Schwartz et al., 2006).
  • Such activities are manifested by increased production of TNF- ⁇ , down-regulation of IGF-I, inhibition of the ability to express MHC-II proteins and thus to act as APCs, and failure to support neural tissue survival and renewal (Butovsky et al., 2006a, 2006b, 2005).
  • Addition of IL-4, a cytokine derived from Th-2 cells, to microglia activated by aggregated A ⁇ can reverse the down-regulation of IGF-I expression, the up-regulation of TNF- ⁇ expression, and the failure to act as APCs (Butovsky et al, 2005).
  • NPC neural stem/progenitor cell
  • Dulbecco's modified Eagles's medium (DMEM)/F12 medium (Gibco/Invitrogen, Carlsbad, CA) containing 2 mM L-glutamine, 0.6% glucose, Merrill et al., 1993.6 ⁇ g/ml putrescine, 6.3 ng/ml progesterone, 5.2 ng/ml sodium selenite, 0.02 mg/ml insulin, 0.1 mg/ml transferrin, 2 ⁇ g/ml heparin (all from Sigma-Aldrich, Rehovot, Israel), fibroblast growth factor-2 (human recombinant, 20 ng/ml), and epidermal growth factor (human recombinant, 20 ng/ml; both
  • NPC neural stem/progenitor cell
  • H Primary microglial culture. Brains from neonatal (PO-Pl) C57B1/6J mice were stripped of their meninges and minced with scissors under a dissecting microscope (Zeiss, Stemi DV4, Germany) in Leibovitz-15 medium (Biological Industries, Kibbutz Beit Ha-Emek, Israel). After trypsinization (0.5% trypsin, 10 min, 37°C/5% CO 2 ), the tissue was triturated.
  • the cell suspension was washed in culture medium for glial cells [DMEM supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich, Rehovot), L-glutamine (1 mM), sodium pyruvate (1 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml)] and cultured at 37°C/5% CO 2 in 75-cm 2 Falcon tissue-culture flasks (BD Biosciences) coated with poly-D-lysine (PDL) (10 mg/ml; Sigma-Aldrich, Rehovot) in borate buffer (2.37 g borax and 1.55 g boric acid dissolved in 500 ml sterile water, pH 8.4) for 1 h, then rinsed thoroughly with sterile, glass-distilled water.
  • DMEM fetal calf serum
  • FCS fetal calf serum
  • L-glutamine 1 mM
  • sodium pyruvate 1 mM
  • penicillin
  • Microglia were shaken off the primary mixed brain glial cell cultures (150 rpm, 37°C, 6 h) with maximum yields between days 10 and 14, seeded (10 5 cells/ml) onto PDL-pretreated 24- well plates (1 ml/well; Corning, New York, NY), and grown in culture medium for microglia [RPMI- 1640 medium (Sigma-Aldrich, Rehovot) supplemented with 10% FCS, L-glutamine (1 mM), sodium pyruvate (1 mM), ⁇ -mercaptoethanol (50 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml)].
  • the cells were allowed to adhere to the surface of a PDL-coated culture flask (30 min, 37°C/5% CO 2 ), and non-adherent cells were rinsed off.
  • Triton X-100 Sigma- Aldrich, Rehovot
  • anti- ⁇ lll-T mouse anti- ⁇ -tubulin
  • a ⁇ human amino-acid residues 1-17 (mouse, clone 6E10; Chemicon) was used.
  • tissue sections were treated with a permeabilization/blocking solution containing 10% FCS, 2% bovine serum albumin, 1% glycine, and 0.05% Triton X-100 (Sigma-Aldrich, St. Louis). Tissue sections were stained overnight at 4°C with specified combinations of the following primary antibodies: rat anti-BrdU (1 :200; Oxford Biotechnology, Kidlington, Oxfordshire, UK), goat anti-doublecortin (anti-DCX) (1 :400; Santa Cruz Biotechnology, Santa Cruz, CA), and mouse anti-neuronal nuclear protein (anti- NeuN) (1 :200; Chemicon).
  • CDl Ib MAC l ; 1 :50; BD-Pharmingen
  • FITC-conjugated IB-4 was used for labeling of microglia.
  • Anti-MHC-II Abs rat, clone IBL-5/22; 1 :50
  • CDl Ic hamster anti-CDl lc (1 : 100; eBioscience, San Diego, CA) was used.
  • Anti-A ⁇ human amino-acid residues 1-17
  • mouse clone 6E10; Chemicon
  • IGF-I human amino-acid residues 1-17
  • TNF- ⁇ goat anti-TNF- ⁇ Abs
  • T cells were detected with anti-CD3 polyclonal Abs (rabbit, 1 : 100; DakoCytomation, CA).
  • Propidium iodide (1 ⁇ g/ml; Molecular Probes, Invitrogen, Carlsbad, CA), was used for nuclear staining.
  • Control sections (not treated with primary antibody) were used to distinguish specific staining from staining of nonspecific antibodies or autofluorescent components. Sections were then washed with PBS and cover-slipped in polyvinyl alcohol with diazabicyclo-octane as anti-fading agent.
  • mice Nineteen adult double-transgenic APP K59SN, M596L + PS1 ⁇ E9 mice of the B6C3-Tg (APPswe, PSENldE9) 85Dbo/J strain (Borchelt et al., 1997) were purchased from The Jackson Laboratory (Bar Harbor, ME) and were bred and maintained in the Animal Breeding Center of The Weizmann Institute of Science. All animals were handled according to the regulations formulated by the Weizmann Institute's Animal Care and Use Committee, and all experiments and procedures were approved by the Weizmann Institute's Animal Care and Use Committee.
  • Microglia were removed from the flasks and immediately co- cultured (5 x 10 4 cells/well) with NPCs (5 x 10 4 cells/well) for 10 days on cover slips coated with MatrigelTM (BD Biosciences) in 24-well plates, in the presence of NPC-differentiation medium. The cultures were then fixed with 2.5% paraformaldehyde in PBS for 30 min at room temperature and stained for neuronal and glial markers.
  • Neurogenesis in the dentate gyrus was evaluated by counting of pre-mature neurons (DCX + ), proliferating cells (BrdU + ), and newly formed mature neurons (BrdU + /NeuN + ) in six coronal sections (370 ⁇ m apart) per mouse brain. To obtain an estimate of the total number of labeled cells per dentate gyrus, the total number of cells counted in the selected coronal sections from each brain was multiplied by the volume index (the ratio between the volume of the dentate gyrus and the total combined volume of the selected sections). Specificity of BrdU+/NeuN+ co-expression was assayed using the confocal microscope (LSM 510) in optical sections at 1- ⁇ m intervals.
  • CD3 + , CDl Ib + and CDl Ic + cells were analyzed from 30-50 A ⁇ -plaques of each mouse tested in this study. Cell counts, numbers of A ⁇ plaques, plaque areas, and intensity of NeuN staining per unit area in the dentate gyrus were evaluated automatically using Image-Pro Plus 4.5 software (Media Cybernetics, Carlsbad, CA).
  • results in-vitro were analyzed by two-tailed unpaired Student's f-test and by the Tukey-Kramer multiple comparisons test (ANOVA) and are expressed as means ⁇ SEM.
  • results in vivo were analyzed by two-tailed unpaired Student's f-test or 1-way ANOVA and are expressed as means ⁇ SEM.
  • Example 1 Aggregated ⁇ -amyloid induces microglia to express a phenotype that blocks neurogenesis, and the blocking is counteracted by IL-4.
  • microglia found in association with inflammatory and neurodegenerative diseases e.g. microglia activated by LPS or by aggregated A ⁇ ( i- 40)
  • IL-4-activated microglia shown to be associated with neural tissue survival, express MHC-II, produce IGF-I, and decrease TNF- ⁇ expression (Butovsky et al, 2005).
  • a ⁇ -activated microglia block neurogenesis, and if so, whether T cell-derived cytokines can counteract the inhibitory effect.
  • NPCs neural stem/progenitor cells
  • a ⁇ ( i -4 o ) rather than A ⁇ ()-42) and it's concentration was based on their previous demonstration that this compound induces cytotoxic activity in microglia (Butovsky et al, 2005). Growth media and cytokine residues were then washed off the co-cultured microglia, and each of the treated microglial preparations was freshly co-cultured with dissociated adult subventricular zone- derived NPC spheres (Butovsky et al., 2006b) on coverslips coated with MatrigelTM in the presence of differentiation medium (Butovsky et al., 2006b) (Fig. 9A).
  • Example 2 T-cell-based vaccination with copolymer-1 modulates immune activity of microglia, eliminates ⁇ -amyloid plaque formation, and induces neurogenesis.
  • the above findings prompted us to examine whether a T cell-based vaccination would alter the default microglial phenotype in AD and hence lead to plaque removal and neurogenesis.
  • the antigen chosen for the vaccination was Cop- 1 and we examined its effect in Tg-AD mice suffering from learning/memory impairment and an accumulation of aggregated A ⁇ plaques deposited mainly in the cortex and the hippocampus, both characteristic features of early-onset familial AD (Borchelt et al., 1997).
  • the regimen for Cop-1 administration was similar to that used to evoke neuroprotection in a model of chronic elevation of intraocular pressure (Bakalash et al., 2005).
  • MHC-II + microglia in these mice were indeed found to express IGF-I (Fig. 10F).
  • most of the T cells in the Cop-1 vaccinated Tg-AD mice were found to be located close to MHC-II + microglia. Any A ⁇ - immunoreactivity detected in those mice appeared to be associated with the MHC- H + microglia, suggesting the occurrence of an immune synapse between these microglia and CD3 + T cells (Fig. 10H).
  • microglia activated by A ⁇ exhibited amoeboid morphology, whereas the rounded shape of the CDl Ic + microglia was pronounced of dendritic cells (Fig. 12B).
  • amoeboid morphology of the A ⁇ -stained microglia was reversible on addition of IL-4, when they again took on the morphological appearance of dendritic-like cells (Fig. 12B).
  • the various treatments applied to the microglia did not affect their expression of CDl Ib, suggesting that they did not lose their CDl Ib characteristics when they took on the expression of CDl Ic (Fig. 12B).
  • Example 3 Copolymer-1 vaccination counteracts cognitive decline in AD. Two weeks before the end of the experiment, all mice were tested in a Morris water maze (MWM) for cognitive activity, as reflected by their performance of a hippocampus-dependent spatial learning/memory task. The MWM performance of the untreated-Tg-AD mice was significantly worse, on average, than that of their age-matched non-Tg littermates (Figs. 15A-15B). However, the performance of Cop-1 -vaccinated Tg-AD mice was superior to that of the untreated-Tg-AD mice and did not differ significantly from that of the non-Tg-AD mice, suggesting that the Cop-1 vaccination had prevented further cognitive loss. Differences in cognitive performance were manifested in both the acquisition (Fig. 15A) and the reversal tasks (Fig. 15B).
  • AD Alzheimer's disease
  • a destructive inflammatory response Using AD double-transgenic mice expressing mutant human genes encoding presenilin 1 and chimeric mouse/human amyloid precursor protein, we showed that switching of the microglia to cells that phenotypically resemble dendritic- like (CDl Ic) cells producing IGF-I, achieved here by a T cell- based vaccination with Cop-1 given according to a specific regimen, resulted in reduction of plaque formation and induction of neurogenesis. The vaccination also led to the attenuation of cognitive decline, assessed by performance in a MWM.
  • CDl Ic dendritic- like
  • microglia activated by aggregated ⁇ -amyloid and characterized as CDl lb + /CDl lc7MHC-II7TNF ⁇ + cells, impeded neurogenesis from adult NPCs, whereas CDl lb + /CDl 1 c7MHC-II7TNFcf microglia, a phenotype induced by IL-4, counteracted the adverse ⁇ -amyloid-induced effect.
  • mice in this study demonstrated attenuated cognitive loss (tested in MWM) and increased neurogenesis. These two aspects of hippocampal plasticity are apparently related to the presence of IGF-I and cognitive activity (Rivera et al., 2005) and cell renewal (Butovsky et al., 2006a, 2006b; Aberg et al., 2000; Lichtenwalner et al., 2001). Reported observations in Tg-AD mice housed in an enriched environment also support a link between mechanisms associated with neurogenesis (Ziv et al., 2006a) and with plaque reduction (Lazarov et al., 2005).
  • aggregated A ⁇ evidently interferes with the ability of microglia to engage in dialog with T cells, its presence in the brain can be expected to cause loss of cognitive ability and impairment of neurogenesis. Homing of CNS-autoreactive T cells to the site of disease or damage in such cases is critical, but will be effective only if those T cells can counterbalance the destructive activity of the aggregated A ⁇ . As shown here, IFN- ⁇ by itself is impotent against the activity of microglia that are already committed to an aggregated A ⁇ phenotype, but is effective when added together with IL-4.
  • IL-4-activated myeloid cells derived from the patient's own peripheral blood or from HLA-matched donor may be used for diagnostics and therapy of acute and chronic neurodegenerative diseases. Such cells are homing only to sites that express danger signals in the form of local expression of ICAM- 1 on distressed brain parenchyma. If the tissue is intact or does not provide distressed signals no trafficking of BM cells will take place
  • BM stem cells give rise to a variety of hematopoietic lineages and repopulate the blood throughout adult life (Fuchs. & Segre, 2000; Weissman, 2000a,b).
  • neural stem cells have the ability to give rise to astrocytes and oligodendrocytes but not microglia (Fricker et al., 1999; Gage, 2000). It has been suggested that microglia are replenished partly by division of resident cells and partly by immigration of circulating monocytes (Lawson et al., 1992).
  • BM transplantation to animals is a common procedure in immunology and stem-cell research.
  • the transplantation requires whole body lethal ⁇ -irradiation but does not neccessitate brain irradiation.
  • the brain it is essential to avoid irradiating the brain which impairs brain neurogenesis and cognitive activity (Monje et al., 2002).
  • recent findings demonstrate that sublethal irradiation induces microglial expression of ICAM- I (CD54) (Nordal & Wong, 2004), which has an important role in development and promotion of adhesion.
  • ICAM-I reacts with CDl I/CD 18, CD l ib/CD 18 or CDl lc/CD18 (integrin receptor expressed on monocytes, macrophages and NK cells, moderate on granulocytes, and least on subsets of T and B cells) resulting in immune reaction and/or inflammation (Frick et al., 2005).
  • Endothelial ICAM-I contributes to the extravasations of leukocytes from blood vessels, particularly in areas of inflammation.
  • ICAM-I on APCs contributes to antigen-specific T cell activation, presumably by enhancing interactions between T cells and APCs.
  • ICAM-I does not show a static level of expression, but is upregulated or downregulated depending on conditions in the microenvironment (van de Stolpe & van der Saag, 1996). Endothelial ICAM-I expression increases in response to a variety of different stimuli (Kilgore et al., 1995; Lum & Roebuck., 2001; Roebuck & Finnegan, 1999).
  • Pro-inflammatory T cell cytokines such as TNF- ⁇ and IFN- ⁇ , increase the expression of cellular adhesion molecules on the endothelial cells, particularly ICAM-I, permitting a tight binding of the T cells to the endothelial cells via their ligands on the surface of T cells (Campbell et al., 1998).
  • heterozygous mice (CX 3 CRlZ 017 ⁇ + ) express both the DTR and GFP on peripheral monocytes, and on a subset of mononuclear phagocytes that include macrophages and dendritic cells (Morris, 1981, van Praag et al., 2000) and by microglia in the CNS (Shaked et al., 2004).
  • BM cells derived from double transgenic mouse model CX 3 CRl GFP /CDl lc DTR described above to the ALS SODl transgenic mice or injected IL-4-activated BM-derived myeloid cells systemically (iv) without ⁇ - irradiation.
  • BM-derived myeloid cells do not migrate into the intact CNS Under normal laboratory conditions, in chimera mice transplanted with BM from double transgenic mise described above, no GFP + cells were found in the CNS (data not shown). However, chimera mice created accordingly to a classical protocol (whole body lethal ⁇ -irradiation) exhibit the presence of GFP + microglia (Figs. 17A, B) coexpressing MHC-II and IGF-I (Fig. 17C).
  • Example 2 Migration of bone marrow-derived cells correlates with increased expression of microglial CDllb + /ICAM-l + under neurodegenerative conditions
  • Example 3 IL-4 activated bone marrow-derived myeloid cells target degenerative CNS: Implication for MS, AD and ALS
  • Bone marrow-derived myeloid cells do not migrate into the intact CNS
  • Th cells directed to autoantigens autoimmune Th cells
  • autoimmune Th cells a phenomenon designated 'protective autoimmunity'
  • cytokines derived from such T cells are active players in the dialogue between T cells and microglia needed for the protective autoimmunity to be manifested (Butovsky et al., 2006b, 2005, 2001 ; Shaked et al., 2005) and maintenance of cell renewal under physiological conditions (Miller et al., 1998).
  • Th-derived cytokine such as IFN- ⁇ or IL-4 may have a role in directing microglia plasticity beyond their innate immune activity.
  • Neonatal (PO-Pl) C57B1/6J mice heterozygous mutant mouse strain in which the CX 3 CRl chemokine receptor gene is replaced with a green fluorescent protein gene (GFP) C57BI/6-CX 3 CRI-GFP [CX 3 CRlZ 3 ⁇ + ) knock-in mice (Jung et al., 2000), and double transgenic mice, expressing GFP under the CX 3 CRI promoter and Diphtheria toxin (DTx) receptor under CDl Ic promoter C57BL/6-CD1 IC-DTR-CX 3 CRI-GFP ⁇ CD11C DTR /CX 3 CR1J GFP/+ ). Mice were supplied by the Animal Breeding Center of The Weizmann Institute of Science and were handled according to the regulations formulated by the Weizmann Institute's Animal Care and Use Committee.
  • GFP green fluorescent protein gene
  • Reagents, ⁇ -amyloid fragment (1-40), Lipopolysaccharide (LPS) (containing ⁇ 1% contaminating proteins; obtained from Escherichia coli 0127:B8) and Diphtheria toxin (DTx; from Corynebacterium diphtheriae) were obtained from Sigma-Aldrich.
  • Recombinant mouse IFN- ⁇ and IL-4 both containing endotoxin at a concentration below 0.1 ng per ⁇ g of cytokine, were obtained from R&D Systems (Minneapolis, MN).
  • Cells obtained from single-cell suspensions were plated (3500 cells/cm 2 ) in 75-cm 2 Falcon tissue-culture flasks (BD Biosciences, Franklin Lakes, NJ), in NPC-culturing medium [Dulbecco's modified Eagles's medium (DMEM)/F 12 medium (Gibco/Invitrogen, Carlsbad, CA) containing 2 raM L-glutamine, 0.6% glucose, Merrill et al., 1993.6 ⁇ g/ml putrescine, 6.3 ng/ml progesterone, 5.2 ng/ml sodium selenite, 0.02 mg/ml insulin, 0.1 mg/ml transferrin, 2 ⁇ g/ml heparin (all from Sigma-Aldrich, Rehovot, Israel), fibroblast growth factor-2 (human recombinant, 20 ng/ml), and epidermal growth factor (human recombinant, 20 ng/ml; both from Peprotech, Rocky Hill
  • Spheres were passaged every 4-6 days and seeded as single cells.
  • Green fluorescent protein (GFP)-expressing neural progenitor cells (NPCs) were obtained as previously described (Vieira et al., 2003). NPC were collected, centrifugated, 110 x g for 10 min at room temperature and then seeded as single cells (5 ⁇ 10 4 cells/well) on cover slips coated with Poly-L-lysine hydrobromide (PLL; Sigma- Aldrich; 0.125 mg/ml) for 1 h, then rinsed thoroughly with sterile, glass-distilled water and coated with Matrigel (BD Biosciences; 1 : 100 in DMEM) for 1 h. cells were grown in differentiation medium (same as the culture medium for NPCs but without growth factors and with 2.5% FCS).
  • PLL Poly-L-lysine hydrobromide
  • Matrigel Matrigel
  • the cell suspension was washed in culture medium for glial cells [DMEM supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich, Rehovot), L-glutamine (1 mM), sodium pyruvate (1 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml)] and cultured at 37°C/5% CO 2 in 75-cm 2 Falcon tissue-culture flasks (BD Biosciences) coated with poly-D-lysine (PDL) (10 mg/ml; Sigma-Aldrich, Rehovot) in borate buffer (2.37 g borax and 1.55 g boric acid dissolved in 500 ml sterile water, pH 8.4) for 1 h, then rinsed thoroughly with sterile, glass-distilled water.
  • DMEM fetal calf serum
  • FCS fetal calf serum
  • L-glutamine 1 mM
  • sodium pyruvate 1 mM
  • penicillin
  • Microglia were shaken off the primary mixed brain glial cell cultures (150 rpm, 37°C, 6 h) with maximum yields between days 10 and 14, and seeded (10 5 cells/ml) onto -pretreated 24-well plates (1 ml/well; Corning, Corning, NY) with Poly-L-lysine hydrobromide (PLL; Sigma- Aldrich; 0.125 mg/ml) and Matrigel (BD Biosciences). The cells were allowed to adhere to the surface (25 min, 37°C/5% CO 2 ), and non-adherent cells were rinsed off.
  • Cells were grown in culture medium for microglia [RPMI- 1640 medium (Sigma- Aldrich, Rehovot) supplemented with 10% FCS, L-glutamine (1 mM), sodium pyruvate (1 mM), ⁇ -mercaptoethanol (50 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml)].
  • RPMI- 1640 medium Sigma- Aldrich, Rehovot
  • FCS L-glutamine
  • sodium pyruvate 1 mM
  • ⁇ -mercaptoethanol 50 mM
  • penicillin 100 U/ml
  • streptomycin 100 mg/ml
  • Neuronal medium Neuronal medium (Rhenium, Israel) supplemented with L- glutamine (1 mM), penicillin (100 U/ml), streptomycin (100 mg/ml), hepes (1 mM) and B-27 (Rhenium, Israel; 1 :50)].
  • Cultures were fixed at the different time points with 2.5% paraformaldehyde (PFA) in PBS for 30 min at room temperature and stained for neuronal and glial markers. Cell proliferation rates in vitro were determined by staining with BrdU, 2.5 ⁇ M (Sigma-Aldrich, St. Louis).
  • Example 1 Microglia treated with IFN- ⁇ express markers of early differentiated neurons
  • the cultures were treated for 10 days with 10 ng/ml IFN- ⁇ (MG,, ⁇ ), or 10 ng/ml IL-4 (MG ⁇ L-4) ), or both MG ( i FN - ⁇ + i L - 4 )- After 10 days the medium was changed and microglia were cultured in neuronal medium containing supplement supportive of neuronal survival without the presence of the indicated cytokines (Fig. 21A).
  • the choice of the dosing of the cytokines was based on our previous studies indicating the IFN- ⁇ at dosages above 20 ng/ml imposed on microglia a phenotype associated with a high level of TNF- ⁇ , which blocks ability of microglia to express growth factors (Butovsky et al., 2006a, 2001) or to act as antigen presenting cells (Butovsky et al, 2005) or to support cell renewal (Butovsky et al., 2006a, 2001).
  • We analyzed the cells by immunocytochemistry analysis using antibodies directed to activated microglia marker (CD l Ib) and to the neuronal lineage marker ( ⁇ lll-Tubulin).
  • IB-4 Fig. 21C
  • IB-4 Fig. 21D
  • the percentage of IB-4 + cells in the culture was not affected by the treatment Fig. 21F.
  • IFN- ⁇ -activated microglia maintained the expression of activated microglial marker CDl Ib, the neural cell marker ⁇ III-T + and in addition expressed ⁇ -aminobutyric acid (GABA) (Fig. 21G), the major inhibitory transmitter in higher brain regions (Soghomonian & Martin, 1998). Because GABA immunoreactivity could potentially result from uptake rather than production of GABA, the cells were also stained for the GABA synthesizing enzyme glutamic acid decarboxylase 67 (GAD-67).
  • GABA GABA synthesizing enzyme glutamic acid decarboxylase 67
  • the IFN- ⁇ treated microglia after 18 days in culture were CDl lb + / ⁇ III-T + /G AD + ) (Fig. 21H).
  • CDl Ib immunoreactivity on ⁇ III-Tubulin + elongated cells was decreased at this stage.
  • Example 2 The microglial origin of the elongated ⁇ III-Tubulin + cells
  • microglia from double transgenic mouse model CX 3 CR l GFP /CDl lc DTR that express GFP under the promoter of the chemokine fractalkine receptor CX 3 CRl (Jung et al., 2000) expressed in microglia (Butovsky et al., 2001, Davalos et al., 2005, Nimmerjahn et al., 2005), and DTR (diphtheria toxin receptor) under CDl Ic promoter (Jung et al., 2002).
  • mice express both the DT-receptor and GFP on microglial cells in the CNS, on peripheral monocytes, and on a subset of mononuclear phagocytes that include macrophages and dendritic cells (Davalos et al., 2005, Geissmann et al., 2003).
  • GFP + microglia obtained from the double transgenic mice were co-labeled with ⁇ -III-Tubulin and doublecortin (DCX), a marker of early differentiated neurons (Kempermann et al, 2004).
  • DCX doublecortin
  • MHC-II-expressing microglia might express, even if only transiently CDl Ic, a marker of dendritic cells (DCs), and if so, by adding the diphtheria toxin (DTx) it would be possible to selectively ablate IFN- ⁇ -responding microglia and thereby the microglia-derived neurons (Gropp et al, 2005).
  • DTx diphtheria toxin
  • DTx was added to the cultures and the cultures were left for additional 6 days before analyzing (Fig. 23B).
  • the DTx treatment resulted in a complete ablation of the ⁇ -III-Tubulin expressing cells (Fig. 23C).
  • Fig. 23C In order to verify that the ⁇ -III-Tubulin expressing cells ablation is not a result of DTx toxic effect on neuronal cells, we treated mixed glia cultures (containing microglia, astroglia, oligodendrocytes and survived neurons) with INF- ⁇ , 2 days later we added the DTx and the culture was left for additional 72 hours before analyzed (Fig. 23D).
  • IFN- ⁇ -treated microglia were sensitive to Dtx. whereas ⁇ III-Tubulin + neurons were not.
  • the survived neurons expressed microtubule associated protein MAP2, a marker of mature neuronal cells.
  • the CDl lb+/ ⁇ III-Tubulin + cells did not express MAP2 at any tested conditions (data not shown). This data supported our hypothesis that indeed the ⁇ - III-Tubulin expressing cells were from microglial origin.
  • Example 3 Stem cell-like nature of microglia Having shown that microglia can give rise to neuronal-like or dendritic-like cells prompted us to examine whether these cells can acquire stem-cell behavior. Interestingly, when GFP + microglia were kept untreated, we found them generating floating spheres expressing Nestin, a neural stem cell marker, and CD34, a marker for hematopoietic stem cells (Krause et al, 1994, Morel et al, 1996) (Fig. 24A).
  • IL-4 but not IFN- ⁇ triggered expression of GFAP without inducing morphological features of astrocytes (Fig. 25A) and increased expression of proteoglycan oligodendrocyte marker NG2 (CDl lb + /NG2 + ) (Fig. 25B).
  • NG2 proteoglycan oligodendrocyte marker NG2
  • Fig. 25B No markers for mature oligodendrocytes such as RIP or MBP were identified in IL-4-treated microglia at any tested conditions.
  • Example 4 Microglia differentiation is impaired when exposed to pathological- associated agents and restored following co-treatment with IL-4.
  • microglia function as the immune cells of the CNS it is meaningful to study their functions under pathological conditions manifested by high levels of IFN- ⁇ , LPS or aggregated A ⁇ peptide.
  • Our previous studies showed that a short exposure of microglia to low levels of IFN- ⁇ confers them a phenotype supportive to neural tissue.
  • exposure to high levels of IFN- ⁇ confer them a cytotoxic phenotype, which can be reversed by the addition of IL-4.
  • IL-4 cytotoxic phenotype
  • microglia become amoeboid resembling microglia treated with 100ng/ml LPS or with aggregated A ⁇ peptide 1-40 (A ⁇ (1 _ 40) ; 5 ⁇ M) which is known to be associated with inflammation (Butovsky et al, 2005).
  • IFN- ⁇ ability to support differentiation into neuronal-like cells could be restored upon addition of IL-4 (10 ng/ml) (Fig. 26).
  • microglial pluropotency goes beyond immune or neural activities, the cells can act as a source of stem cells when encountering T-cell-derived cytokines. It is well established that the microglia resides in the brain parenchyma
  • microglial pluripotency includes ability to act as stem- like cells which give rise to neuronal-like cells.
  • MHC-II found in sites of degenerative conditions are by no means markers of destructive microglia or markers of degenerative conditions. On the contrary, neither absence of IFN- ⁇ or high dose IFN- ⁇ induces MHC-II expression.
  • CD 1 1 c within the brain might be viewed as a marker of either progenitor neuronal-like cells emerging from microglia, or as a marker of IL-4-activated microglia that supports neural tissue survival and renewal.
  • CDl Ic expression is linked to DTR expression revealed that CDl lc-expressing cells are the origin of neuronal cells or the cells that support rather than destroy neuronal cells.
  • Microglia origin is the hematopoietic cells, and indeed the stem cells that were formed in the microglial culture expressed CD34, a marker of hematopoietic origin, unlike that of adult neural stem cells isolated from SVZ that do not express CD34. It is possible that the adult stem cells found in the healthy brain in neurogenic niches serve as a reservoir of cell renewal under non-pathological conditions. Under pathological conditions, it is very likely that bone marrow- derived local microglia cells, assisted by the T cells, create the "repairing" neurogenic niches. If this is the case, the microglia perform the dual action of forming the niche for the cell renewal and serving as the origin for the renewing cells. Such niches are replenished by bone marrow-derived cells (Brazelton et al., 2000, Mezey et al., 2000, Cogle et al., 2004).
  • hematopoietic stem cells can locally differentiate into neuronal cells (Wagers et al., 2002). It is possible that such trans- differentiation, although not taking place under normal conditions, does take place under pathological conditions assisted by the local immune response. Alternatively, the neuronal-like cells endorse the diseased sites with neuronal-like features needed for the attraction of the resident neural stem cells and for the molecular clues needed for their differentiation into new neurons. Other studies have reported that microglia can become stem cells in in vitro conditions but this has been shown only with a high percentage of serum (Yokoyama et al., 2004).
  • the microglial-derived neuronal-like cells found in the present study expressed GABA, and GABAergic excitation with GABA A -R agonists has been found to induce neuronal differentiation of adult progenitor cells (Tozuka et al, 2005). It is therefore possible that the IFN-activated microglia can support neurogenesis from endogenous stem-cell pools by their microglial nature as our previous studies demonstrated, or via their neuronal-like GABAergic nature, or both. Chronic pathological conditions are manifested by high levels of IFN- ⁇ (autoimmune diseases such as multiple sclerosis), or aggregated ⁇ -amyloid microglia (e.g. Alzheimer's disease).
  • IFN- ⁇ autoimmune diseases such as multiple sclerosis
  • aggregated ⁇ -amyloid microglia e.g. Alzheimer's disease
  • microglia associated with such conditions are cytotoxic (Butovsky et al, 2005) and block cell renewal (Butovsky et al., 2006a, 2001).
  • Compounds associated with neurodegeneration aggregated A ⁇ o ) or high levels of IFN- ⁇ up-regulate the expression of TNF- ⁇ by microglia (Butovsky et al., 2006a, 2005).
  • the phenotype of the microglia was correlated with a signal transduction pathway that down-regulates expression of MHC-II through the MHC-II-transactivator which involves STAT-I activation.
  • Amyotrophic lateral sclerosis is a terminal disease characterized by loss of motor neurons associated with microglial activity. We postulated that the local immune response plays a dual role, by demarcating endangered sites and — if appropriately controlled — by defensive action. Using transgenic ALS mouse model, we show that distress signals appear relatively late and that the late phase of disease progression associated with diminished microglial activity. In chimeric ALS mice whose bone marrow (BM)-derived myeloid cells express GFP, the diseased spinal cord was populated by dendritic-like BM-derived microglia expressing IGF- I.
  • BM bone marrow
  • IL-4-activated BM-derived myeloid cells expressing both CDl Ic and IGF-I injected peripherally, homed to spinal cord motor neurons, and maintained their phenotype.
  • Inflammation was recently implicated as a critical mechanism responsible for the progressive nature of neurodegenerative diseases (Minghetti et al, 2005, Wyss- Coray & Mucke, 2002), including Alzheimer's, Parkinson's, and Huntington's diseases, ALS, multiple sclerosis, prion diseases, and many other less common syndromes.
  • the role of inflammation is known to differ in different diseases. All of the abovementioned neurodegenerative diseases typically involve deposits of inclusion bodies that contain abnormal protein folding that is associated with neuronal toxicity (Ross & Poirier, 2004; Taylor et al., 2002). We suggest that the nature and timing of the inflammatory response are determined by the site of protein deposition.
  • misfolded proteins activate a programmed cell-death pathway within the neurons, whereas in Alzheimer's disease the misfolded proteins accumulate externally and are sensed by microglia (Butovsky et al, 2006c; Akiyama & McGeer, 1990).
  • mice were supplied by the Animal Breeding Center of The Weizmann Institute of Science and handled according to the regulations formulated by the Weizmann Institute's Animal Care and Use Committee.
  • H Reagents. Recombinant mouse IL-4 (containing endotoxin at a concentration below 0.1 ng per ⁇ g cytokine) from R&D Systems.
  • Cells were collected and centrifuged (10 min, 1000 rpm, 4 0 C), resuspended, and then seeded (7x lO 6 cells) in 10 ml of microglial medium [RPMI- 1640 medium supplemented with 10% FCS, L-glutamine (1 mM), sodium pyruvate (1 mM), ⁇ -mercaptoethanol (50 ⁇ M), penicillin (100 U/ml) and streptomycin (100 U/ml)], and cultured at 37°C/5% CO 2 in 75-cm 2 tissue-culture flasks coated with poly-D-lysine in borate buffer (pH 8.4) (Butovsky et al., 2006b).
  • IL-4-activated wild-type BM cells were evaluated by transplantation of IL-4- activated BM donor cells from non-mSOD l-CX 3 CRl/ GFP/+ mice (2-5 x 10 5 cells in a volume of 0.1 ml) into the tail vein of non-irradiated diseased F2-SOD1 mice every 5 days, starting from day 125. Purity of the cells was assessed by FACS analysis or by immunocytochemistry after staining with antibodies (Abs) against Mac-1 (CDl Ib) (Pharmingen), and was found to be >95%.
  • PBMCs were purified by gradient centrifugation. For this purpose, peripheral blood was diluted (1 : 1 ratio) with PBS and stratified on 4 ml Ficoll-Paque (Amersham) in 15-ml conical tubes, which were then centrifuged at 400 ⁇ g for 30 min at 20°C. Recovered PBMCs were washed twice with PBS by centrifugation at 100 ⁇ g for 10 min at 4 0 C. Viability of the pelletted PBMCs was determined by staining with trypan blue (Sigma).
  • PBMCs FACS analysis of human PBMCs.
  • PBMCs were isolated from human blood and double stained with the cell-surface markers mouse anti-human CDl Ic mAb (IgG, PE-labeled; BD Biosciences-Pharmingen) and Lineage Cocktail 1 (Hn 1 ; BD Biosciences-Pharmingen).
  • the latter includes antibody clones against CD3, CD14, CD16, CD19, CD20, and CD56, which, in combination, stain lymphocytes, monocytes, eosinophils, and neutrophils (IgG, FITC-labeled; BD Biosciences-Pharmingen).
  • the percentages of CDl lc d ⁇ m /Lin ⁇ were determined by flow cytometric analysis using a FACScan (Becton Dickinson) and CELLQUEST software.
  • Sections were stained with the activated microglia marker rat anti-CDl lb, (MACl; 1 :50 dilution; BD-Pharmingen), hamster anti-CDl lc (1 :50; eBioscience, San Diego), goat anti-IGF-I (1 :50 dilution; R&D Systems), and hamster anti-ICAM- 1 (1 :50 dilution; Chemicon) in PBS with 10% of the permeabilization/blocking solution. Sections were incubated with the primary antibody for 24 h at 4°C, washed with PBS, and incubated with the secondary antibodies in PBS for 1 h at room temperature while being protected from light.
  • MACl activated microglia marker rat anti-CDl lb
  • hamster anti-CDl lc (1 :50; eBioscience, San Diego
  • goat anti-IGF-I (1 :50 dilution; R&D Systems
  • hamster anti-ICAM- 1 (1
  • Q-PCR reactions were performed according to the manufacturer's instructions, using Absolute QPCR SYBR ® Green ROX mix (ABgene) containing Thermo-start ® DNA polymerase, dNTPs, MgCl 2 , and SYBR Green I dye and ROX reference dye.
  • Q-PCR products were detected by the SYBR Green I dye detector absorbed at 519 nm, obtained in triplicate for each of the cDNA samples using the Rotor-Gene 6 instrument (Corbett Research), and analyzed using Rotor-Gene 6000 software (version 1.7, Corbett).
  • Relative mRNA amounts were evaluated by the relative standard curve method (Livak et al., 2001), assuming similar PCR efficiencies of the gene of interest relative to an endogenous reference gene.
  • Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cytoplasmic ⁇ -actin (ACTB) were chosen as reference genes.
  • the amplification cycle was 95 0 C for 5 s, 60 0 C for 20 s, and 72°C for 15 s.
  • IGF-I sense, S'-TTCAGTTCGTGTGTGGACCGAG-S'; (SEQ ID NO: 1) antisense, 5'-TCCACAATGCCTGTCTGAGGTG-3 r ; (SEQ ID NO:2) for the reference gene GAPDH: sense, 5'-AATGTGTCCGTCGTGGATCTGA-S'; (SEQ ID NO:3) antisense, S'-GATGCCTGCTTCACCACCTTCT-S'; (SEQ ID NO:4) and for the reference gene ACTB: sense 5'-GACGGCCAGGTCATCACTAT-S'; (SEQ ID NO:5) antisense, S'-AAGGAAGGCTGGAAAAGAGC-S'. (SEQ ID NO:6)
  • Example 3 Injected bone marrow-derived myeloid cells home to the spinal cords of SOD mice and maintained their ability to express CDlIc.
  • CDl lc + /IGF-I + cells are functionally reminiscent of microglia activated by the cytokine IL-4 (Butovsky et al., 2006a, 2006c).
  • IL-4-activated microglia express a dendritic-like phenotype, which is characterized by CDl Ic and IGF-I expression, and can induce both neuroprotection and neural cell renewal (Butovsky et al., 2006a, 2006b, 2006c, 2005).
  • the BM-derived recruited cells expressing IGF-I in these mice homed primarily to the grey matter of the ventral horn, or in other words, to the sites of dying motor neurons (Fig. 29B, inset).
  • Example 4 BM-derived cells isolated and cultured from end-stage SOD mice and from wild-type mice express similar levels of CDlIc and IGF-I.
  • IGF-I has been shown to play a key role in cell survival and renewal in the CNS (Shaked et al., 2004; Butovsky et al, 2005; Aberg et al., 2000; Dudek et al., 1997; Kaspar et al., 2003). That finding, together with the recent demonstration that attenuation of SODl expression by microglia in 90-day- old ALS mice significantly extends their life expectancy (Boillee et al., 2006), can be taken to argue that the microglia in ALS mice make a late negative contribution to disease progression but do not affect disease onset. Our present results are in line with this notion, and support the contention that the local immune cells recruited in ALS have a late and negative effect.
  • the recruited BM-derived cells if suitably activated, not only are not toxic but also express IGF- I, they can be viewed as agents of safe self-delivery of IGF-I to sites of motor neuron loss, thus replacing the need for gene therapy as a means of delivery of this growth factor (Kaspar et al., 2003).
  • replacement of the bone marrow of SOD mice with wild-type bone marrow can extend the life expectancy of SOD mice, an effect that might be attributable largely to neurogenesis (Corti et al., 2004).
  • ALS Motor neurons in ALS die by apoptosis (Rabizadeh et al., 1995). Apoptosis is viewed as silent death in that it is not accompanied by signals that activate an immune cascade.
  • the apoptotic death in ALS has been likened to the process that occurs during development, primarily in the nervous system, where growth-factor deprivation acts as the death-inducing signal and eliminates superfluous neurons without intentionally sending a signal for help.
  • the apoptotic death that occurs during development is purposefully programmed, and as there is no need for repair or restoration, the lack of a danger signal can be assumed to be intentional.
  • IGF-I is a key therapeutic factor in ALS (Kaspar et al., 2003), and since it can be supplied by cells that serve to repopulate CNS parenchyma, such cells would appear to be the safest agents for self-delivery of the potential therapy. It is also important to note that the cells home to the motor neuron vicinity and not to the white matter, suggesting self-navigation to an immunological niche that is specifically formed in sites of need.
  • BM-derived myeloid cells from ALS patients can be activated ex vivo by IL-4 and used as an autologous cell therapy. If their own cells cannot be suitably activated, it might be necessary to acquire the required ex-v/vo-activated myeloid cells from matched donors. In either case, it might be worth focusing on deficiency of dendritic-like myeloid cells as a possible biological marker, and on IL-4-activated dendritic-like cells as a potential therapy.
  • Butovsky, O. et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
  • Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 127, 2518-32 (2004).
  • the LPS receptor (CD 14) links innate immunity with Alzheimer's disease. Faseb J 18, 203-5 (2004). Frenkel, D., Maron, R., Burt, D. S. & Weiner, H. L. (2005) J Clin Invest 115,
  • Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 94, 289-98 (2005).
  • Tumor necrosis factor alpha inhibits insulin-like growth factor I-induced hematopoietic cell survival and proliferation. Endocrinology 145, 3101-5 (2004). Sheng, J. G., Mrak, R. E. & Griffin, W. S. (1998) Acta Neuropathol (Berl)
  • Simard, A.R. & Rivest, S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. Faseb J 18, 998-1000 (2004). Simard, A.R., Soulet, D., Gowing, G., Mien, J.P. & Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502 (2006).
  • Leukocyte integrin P150,95 functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium. J Immunol 146, 648-55 (1991 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une préparation cellulaire constituée de cellules myéloïdes dérivées de la moelle osseuse CD11c+, laquelle préparation sert à favoriser la réparation d'un tissu corporel endommagé. Lorsqu'elles sont étiquetées à l'aide d'un agent d'imagerie approprié, ces cellules peuvent servir à détecter et à localiser un tissu corporel endommagé. Ces cellules sont obtenues par activation de cellules myéloïdes dérivées de la moelle osseuse avec une cytokine, de préférence IL-4.
EP07766828A 2006-06-28 2007-06-28 Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé Withdrawn EP2043666A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80605506P 2006-06-28 2006-06-28
US80726406P 2006-07-13 2006-07-13
PCT/IL2007/000797 WO2008001379A2 (fr) 2006-06-28 2007-06-28 Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé

Publications (1)

Publication Number Publication Date
EP2043666A2 true EP2043666A2 (fr) 2009-04-08

Family

ID=38846103

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07766828A Withdrawn EP2043666A2 (fr) 2006-06-28 2007-06-28 Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé

Country Status (2)

Country Link
EP (1) EP2043666A2 (fr)
WO (1) WO2008001379A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273253B2 (en) 2007-03-02 2012-09-25 Smith & Nephew Plc Apparatus and method for filter cleaning by ultrasound, backwashing and filter movement during the filtration of biological samples

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107988157B (zh) * 2017-11-28 2020-12-15 航天中心医院 一种树突状细胞诱导培养基及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056998A2 (fr) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methodes de therapie cellulaire, neurogenese et oligodendrogenese

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008001379A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273253B2 (en) 2007-03-02 2012-09-25 Smith & Nephew Plc Apparatus and method for filter cleaning by ultrasound, backwashing and filter movement during the filtration of biological samples
US8777017B2 (en) 2007-03-02 2014-07-15 Smith & Nephew, Inc. Apparatus and method for filter cleaning by ultrasound, backwashing and filter movement during the filtration of biological samples

Also Published As

Publication number Publication date
WO2008001379A2 (fr) 2008-01-03
WO2008001379A3 (fr) 2009-04-30

Similar Documents

Publication Publication Date Title
Zhou et al. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow
ME Abdel-Salam Stem cell therapy for Alzheimer's disease
US11957713B2 (en) Compositions and methods for treating diseases and disorders of the central nervous system
Koronyo‐Hamaoui et al. Attenuation of AD‐like neuropathology by harnessing peripheral immune cells: Local elevation of IL‐10 and MMP‐9
Xiao et al. Neural stem cell-based regenerative approaches for the treatment of multiple sclerosis
EP1827108B1 (fr) Induction de neurogenese et therapie par cellules souches en combinaison avec le copolymere 1
Lee et al. Cell source-dependent in vivo immunosuppressive properties of mesenchymal stem cells derived from the bone marrow and synovial fluid of minipigs
Nissen et al. Tuftsin‐driven experimental autoimmune encephalomyelitis recovery requires neuropilin‐1
US20090010873A1 (en) Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis
Magga et al. Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer’s disease
Weinger et al. MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination
Wu et al. Enhanced alleviation of aGVHD by TGF‐β1‐modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells
JP5412280B2 (ja) 加齢性黄斑変性症の治療法
Melone et al. Huntington's disease: new frontiers for molecular and cell therapy
Feng et al. Developing hypoimmunogenic human iPSC‐derived oligodendrocyte progenitor cells as an off‐the‐shelf cell therapy for myelin disorders
WO2008001379A2 (fr) Cellules myéloïdes activées servant à favoriser la réparation des tissus et à détecter un tissu endommagé
US20230398153A1 (en) A method for efficient microglia replacement
CA2614666A1 (fr) Inflammation
CN115697391A (zh) 改良的疫苗制剂
WO2017031341A1 (fr) Compositions et méthodes pour traiter la réaction du greffon contre l'hôte
KR101503020B1 (ko) 뉴로펩티드 y를 유효성분으로 포함하는 골다공증의 예방 또는 치료용 약학적 조성물
Taupin Stem Cells and Regenerative Medicine: Volume III: Pharmacology and Therapy
Losurdo A NEW HOPE FOR ALZHEIMER’S DISEASE FROM PRECONDITIONED BONE MARROW MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES: ANALYSIS OF THE IMMUNOMODULATORY EFFECTS
Cheng Evaluating the Functional Contributions of Microglia in Host Defense and Disease in a Model of Mouse Coronavirus-Induced Neurologic Disaese
Hakim Immune Cells and Stem Cells in Spinal Cord Injury: Defining Spinal Cord Injury Associated Microglia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090430

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101ALI20090505BHEP

Ipc: G01N 33/53 20060101ALI20090505BHEP

Ipc: A01N 65/00 20090101ALI20090505BHEP

Ipc: A61K 39/38 20060101ALI20090505BHEP

Ipc: A61K 39/395 20060101ALI20090505BHEP

Ipc: A61K 38/19 20060101ALI20090505BHEP

Ipc: A61K 35/30 20060101AFI20090505BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100205